1	"A patient with <e1>severe cholestatic jaundice</e1> induced by <e2>captopril</e2> is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2	"<e1>Captopril</e1> -associated "<e2>pseudocholangitis</e2>'."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3	"<e1>Captopril</e1> is known to be associated with <e2>dermatologic, hematologic, and pulmonary adverse effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4	"Patients treated with <e1>captopril</e1> who develop "<e2>atypical cholangitis</e2>" should be suspected of having <e1>captopril</e1> -associated liver damage."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5	"Patients treated with <e1>captopril</e1> who develop "atypical cholangitis" should be suspected of having <e1>captopril</e1> -associated <e2>liver damage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6	"Development of <e1>nephrotic syndrome</e1> in a patient with acute myeloblastic leukemia after treatment with <e2>macrophage-colony-stimulating factor</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7	"It should be emphasized that the recurrence of <e1>nephrotic syndrome</e1> was observed after the following chemotherapy, including <e2>M-CSF</e2>, whereas the bone marrow still remained completely remitted."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

8	"The possibility can be raised that <e1>M-CSF</e1> accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of <e2>nephrotic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

9	"The possibility can be raised that <e1>M-CSF</e1> accelerated the underlying <e2>renal disease</e2> in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

10	"These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the <e1>M-CSF</e1> treatment and <e2>macrophage-related glomerular injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

11	"We describe a patient with acute myeloblastic leukemia (AML) who developed <e1>nephrotic syndrome</e1> after receiving several courses of chemotherapy, including <e2>macrophage-colony-stimulating factor</e2> (M-CSF)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

12	"We describe a patient with acute myeloblastic leukemia (AML) who developed <e1>nephrotic syndrome</e1> after receiving several courses of chemotherapy, including macrophage-colony-stimulating factor (<e2>M-CSF</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

13	"On the fifth day of tocolysis with magnesium sulfate, nifedipine, terbutaline and <e1>betamethasone</e1>, <e2>edema</e2> developed in both labia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

14	"On the fifth day of tocolysis with <e1>magnesium sulfate</e1>, nifedipine, terbutaline and betamethasone, <e2>edema</e2> developed in both labia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

15	"On the fifth day of tocolysis with magnesium sulfate, <e1>nifedipine</e1>, terbutaline and betamethasone, <e2>edema</e2> developed in both labia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

16	"On the fifth day of tocolysis with magnesium sulfate, nifedipine, <e1>terbutaline</e1> and betamethasone, <e2>edema</e2> developed in both labia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

17	"<e1>Milk-alkali syndrome</e1> induced by <e2>1,25(OH)2D</e2> in a patient with hypoparathyroidism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

18	"This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and <e1>calcitriol</e1> resulting in two admissions to the hospital for <e2>milk-alkali syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

19	"This article presents a patient with hypoparathyroidism who was treated with <e1>calcium carbonate</e1> and calcitriol resulting in two admissions to the hospital for <e2>milk-alkali syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

20	"After receiving 3 doses of <e1>ifosfamide</e1>/mesna, she was found to be <e2>unresponsive</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

21	"After receiving 3 doses of ifosfamide/<e1>mesna</e1>, she was found to be <e2>unresponsive</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

22	"CONCLUSIONS: There was a temporal relationship between the onset of <e1>nonconvulsive status epilepticus</e1> and initiation of <e2>ifosfamide</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

23	"DISCUSSION: <e1>Central nervous system (CNS) toxicity</e1> has been described with <e2>ifosfamide</e2>, with most cases reported in the pediatric population."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

24	"<e1>Ifosfamide</e1> -induced <e2>nonconvulsive status epilepticus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

25	"OBJECTIVE: To describe a patient with <e1>ifosfamide</e1> -induced <e2>nonconvulsive status epilepticus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

26	"This represents the first report of <e1>nonconvulsive status epilepticus</e1> induced by <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

27	"<e1>Albendazole</e1> -induced <e2>pseudomembranous colitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

28	"Although a few case reports link <e1>metronidazole</e1> with the development of <e2>pseudomembranous colitis</e2>, albendazole has not been associated with the development of this condition."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

29	"While undergoing treatment with <e1>albendazole</e1>, he developed worsening diarrhea with <e2>abdominal pain</e2> and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

30	"While undergoing treatment with <e1>albendazole</e1>, he developed worsening diarrhea with abdominal pain and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

31	"While undergoing treatment with <e1>albendazole</e1>, he developed <e2>worsening diarrhea</e2> with abdominal pain and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

32	"<e2>Aluminum</e2> intoxication, along with other factors, was considered to be the cause of TC development."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

33	"<e1>Aluminum</e1> intoxication, along with other factors, was considered to be the cause of <e2>TC</e2> development."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

34	"<e1>Oculomotor disturbances</e1> associated with <e2>5-fluorouracil</e2> chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

35	"The ocular motor disturbances are probably an expression of regional <e1>5-FU</e1> <e2>neurotoxicity</e2> primarily affecting the brain stem."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

36	"The <e1>ocular motor disturbances</e1> are probably an expression of regional <e2>5-FU</e2> neurotoxicity primarily affecting the brain stem."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

37	"Two patients treated with <e1>5-fluorouracil</e1> (5-FU) for disseminated adenocarcinoma of the colon developed <e2>cerebellar dysfunction</e2> typical of 5-FU neurotoxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

38	"Two patients treated with 5-fluorouracil (<e1>5-FU</e1>) for disseminated adenocarcinoma of the colon developed <e2>cerebellar dysfunction</e2> typical of <e1>5-FU</e1> neurotoxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

39	"Two patients treated with 5-fluorouracil (<e1>5-FU</e1>) for disseminated adenocarcinoma of the colon developed <e2>cerebellar dysfunction</e2> typical of <e1>5-FU</e1> neurotoxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

40	"Two patients treated with <e1>5-fluorouracil</e1> (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

41	"Two patients treated with 5-fluorouracil (<e1>5-FU</e1>) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of <e1>5-FU</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

42	"Two patients treated with 5-fluorouracil (<e1>5-FU</e1>) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of <e1>5-FU</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

43	"Assessment of cortisol response was by <e1>insulin</e1> -induced <e2>hypoglycaemia</e2> in three cases, by short tetracosactrin test in two, and by low-dose tetracosactrin and 24-hour urinary cortisol/creatinine ratio in one."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

44	"FINDINGS: Six children with growth retardation noted after treatment with high-dose <e1>fluticasone propionate</e1> were found to have <e2>adrenal suppression</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

45	"FINDINGS: Six children with <e1>growth retardation</e1> noted after treatment with high-dose <e2>fluticasone propionate</e2> were found to have adrenal suppression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

46	"<e1>Growth and adrenal suppression</e1> in asthmatic children treated with high-dose <e2>fluticasone propionate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

47	"INTERPRETATION: When high doses of <e1>fluticasone propionate</e1> are used, growth may be retarded and <e2>adrenal suppression</e2> may occur."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

48	"INTERPRETATION: When high doses of <e1>fluticasone propionate</e1> are used, <e2>growth may be retarded</e2> and adrenal suppression may occur."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

49	"METHODS: <e1>Growth retardation</e1> was observed in six severely asthmatic children after introduction of high-dose <e2>fluticasone propionate</e2> treatment (dry powder)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

50	"<e1>Metipranolol</e1> associated <e2>granulomatous anterior uveitis</e2>: not so uncommon as thought."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

51	"Two case reports of <e1>bilateral granulomatous anterior uveitis</e1> are described in patients with open angle glaucoma treated with <e2>metripranolol</e2> 0.6% eye drops."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

52	"A review of the literature found 11 children and 2 adults in whom intranasal <e1>desmopressin</e1> was associated with hyponatremia, all of whom experienced seizures or <e2>altered mental status</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

53	"A review of the literature found 11 children and 2 adults in whom intranasal <e1>desmopressin</e1> was associated with <e2>hyponatremia</e2>, all of whom experienced seizures or altered mental status."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

54	"A review of the literature found 11 children and 2 adults in whom intranasal <e1>desmopressin</e1> was associated with hyponatremia, all of whom experienced <e2>seizures</e2> or altered mental status."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

55	"Intranasal <e1>desmopressin</e1> -induced <e2>hyponatremia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

56	"When vague symptoms develop during <e1>desmopressin</e1> therapy, <e2>hyponatremia</e2> must be considered as part of the differential diagnosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

57	"When <e1>vague symptoms</e1> develop during <e2>desmopressin</e2> therapy, hyponatremia must be considered as part of the differential diagnosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

58	"Within 24 hours of fluid restriction and cessation of <e1>desmopressin</e1>, her symptoms and <e2>hyponatremia</e2> resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

59	"Without other causes for the <e1>hyponatremia</e1>, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by <e2>desmopressin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

60	"Without other causes for the hyponatremia, she was diagnosed with the <e1>syndrome of inappropriate antidiuretic hormone</e1>, presumably caused by <e2>desmopressin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

61	"<e1>Uveitis</e1> during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, <e2>clarithromycin</e2> and ethambutol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

62	"<e1>Uveitis</e1> during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and <e2>ethambutol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

63	"<e1>Uveitis</e1> during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of <e2>rifabutin</e2>, clarithromycin and ethambutol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

64	"Does <e1>acyclovir</e1> <e2>increase serum lithium levels</e2>?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

65	"Six days after starting <e1>acyclovir</e1> she exhibited signs of <e2>lithium toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

66	"Six days after starting acyclovir she exhibited signs of <e2>lithium</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

67	"This case suggests that <e1>acyclovir</e1> when given intravenously in doses of 10 mg/kg may result in <e2>increased serum lithium</e2> concentrations."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

68	"This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum <e2>lithium</e2> concentrations."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

69	"Until additional data are available, if intravenous <e1>acyclovir</e1> is administered concurrently with lithium, we recommend closely monitoring patients for signs of <e2>lithium toxicity</e2> and measuring serum lithium levels every second or third day."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

70	"Until additional data are available, if intravenous acyclovir is administered concurrently with <e1>lithium</e1>, we recommend closely monitoring patients for signs of <e1>lithium</e1> toxicity and measuring serum <e1>lithium</e1> levels every second or third day."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

71	"When measured, the <e1>serum lithium level had increased</e1> 4-fold during <e2>acyclovir</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

72	"When measured, the serum <e2>lithium</e2> level had increased 4-fold during acyclovir therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

73	"<e2>Dapsone</e2> syndrome in cutaneous lupus erythematosus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

74	"Physicians should be aware of the potentially <e1>lethal</e1> side effects of <e2>dapsone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

75	"We describe 2 patients with cutaneous lupus erythematosus who developed severe <e2>dapsone</e2> reaction after low dose therapy, with a fatal outcome in one."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

76	"We describe 2 patients with cutaneous lupus erythematosus who developed severe <e1>dapsone</e1> reaction after low dose therapy, with a <e2>fatal</e2> outcome in one."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

77	"A case is presented which illustrates a probably <e1>fatal interaction</e1> between <e2>minoxidil</e2> and a coagulation disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

78	"Nephrogenic diabetes insipidus (<e1>NDI</e1>) is a well-documented complication of <e2>lithium</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

79	"<e1>Nephrogenic diabetes insipidus</e1> (NDI) is a well-documented complication of <e2>lithium</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

80	"Potential mechanisms regarding the pathophysiology of <e1>lithium</e1> -associated <e2>CDI</e2> are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

81	"The association of central diabetes insipidus (<e1>CDI</e1>) with <e2>lithium</e2> use is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

82	"The association of <e1>central diabetes insipidus</e1> (CDI) with <e2>lithium</e2> use is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

83	"This case emphasizes the importance of the evaluation of <e1>lithium</e1> -associated <e2>polyuria</e2> with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

84	"To the best of our knowledge, this is the first case of <e1>lithium</e1> -associated <e2>CDI</e2> and NDI presenting concurrently."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

85	"To the best of our knowledge, this is the first case of <e1>lithium</e1> -associated CDI and <e2>NDI</e2> presenting concurrently."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

86	"<e1>Transient central diabetes insipidus</e1> in the setting of underlying chronic nephrogenic diabetes insipidus associated with <e2>lithium</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

87	"We report a patient receiving chronic <e1>lithium</e1> therapy who presented with a transient <e2>CDI</e2> occurring in the setting of underlying chronic NDI."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

88	"CASE: We report a case of a woman with severe <e1>human insulin</e1> -induced <e2>lipoatrophy</e2> who has been treated exclusively with recombinant DNA <e1>human insulin</e1> since the onset of IDDM."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

89	"CASE: We report a case of a woman with severe human insulin-induced <e1>lipoatrophy</e1> who has been treated exclusively with <e2>recombinant DNA human insulin</e2> since the onset of IDDM."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

90	"CONCLUSIONS: Jet-injection devices might constitute a helpful method to treat those patients affected by severe <e1>human insulin</e1> -induced <e2>lipoatrophy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

91	"<e1>Human insulin</e1> -induced <e2>lipoatrophy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

92	"OBJECTIVE: To evaluate the efficacy of the administration of insulin by a jet-injector device in stopping and reversing severe <e1>human insulin</e1> -induced <e2>lipoatrophy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

93	"Improved awareness of and further investigation into the <e1>neurotoxic effects</e1> of <e2>ofloxacin</e2> may enhance its safe use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

94	"<e1>Seizures</e1> associated with <e2>ofloxacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

95	"The <e1>renal insufficiency</e1> of three patients and the timing of the seizures implicate accumulation of <e2>ofloxacin</e2> as a contributing factor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

96	"The renal insufficiency of three patients and the timing of the <e1>seizures</e1> implicate accumulation of <e2>ofloxacin</e2> as a contributing factor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

97	"We describe four patients who had <e1>seizures</e1> while receiving <e2>ofloxacin</e2>; no other causes were evident."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

98	"A patient is described with the characteristic features of <e1>phenytoin</e1> hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and <e2>abnormal liver function tests</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

99	"A patient is described with the characteristic features of <e1>phenytoin</e1> hypersensitivity syndrome (PHS) including fever, <e2>erythroderma</e2>, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

100	"A patient is described with the characteristic features of <e1>phenytoin</e1> hypersensitivity syndrome (PHS) including <e2>fever</e2>, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

101	"A patient is described with the characteristic features of <e2>phenytoin</e2> hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

102	"A patient is described with the characteristic features of <e1>phenytoin</e1> hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, <e2>pinhead-sized facial pustules</e2> and abnormal liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

103	"A patient is described with the characteristic features of <e1>phenytoin</e1> hypersensitivity syndrome (PHS) including fever, erythroderma, <e2>tibial and facial oedema</e2>, pinhead-sized facial pustules and abnormal liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

104	"Systemic corticosteroids in the <e2>phenytoin</e2> hypersensitivity syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

105	"A patient is described who developed a poorly differentiated <e1>sarcoma</e1> after <e2>cyclophosphamide</e2> was used to treat his rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

106	"<e1>Sarcoma</e1> complicating therapy with <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

107	"A chronic reaction associated with long-term treatment with <e1>nitrofurantoin</e1> has also been reported and causes irreversible <e2>pulmonary fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

108	"<e1>Acute pulmonary reactions</e1> to <e2>nitrofurantoin</e2> are an uncommon side effect of therapy and can cause minor or life-threatening pulmonary dysfunction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

109	"Acute pulmonary reactions to <e1>nitrofurantoin</e1> are an uncommon side effect of therapy and can cause minor or life-threatening <e2>pulmonary dysfunction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

110	"Despite the known <e1>pulmonary side effects</e1> of <e2>nitrofurantoin</e2>, there is no report of this toxicity occurring in pregnant patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

111	"<e1>Nitrofurantoin</e1> -induced <e2>pulmonary toxicity</e2> during pregnancy: a report of a case and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

112	"We present a case of <e1>respiratory failure</e1> occurring in a woman at 16 weeks' gestation who was being treated with <e2>nitrofurantoin</e2> for a urinary tract infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

113	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and <e2>agranulocytosis</e2>, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

114	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, <e2>an infectious mononucleosis-like syndrome</e2>, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

115	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, <e2>cholestatic jaundice</e2>, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

116	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, <e2>cutaneous eruptions</e2>, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

117	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of <e2>leukopenia</e2> and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

118	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and <e2>minor neurological and gastrointestinal complaints</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

119	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, <e2>nephrotic syndrome</e2>, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

120	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, <e2>peripheral neuropathy</e2>, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

121	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, <e2>psychosis</e2>, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

122	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, <e2>renal papillary necrosis</e2>, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

123	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, <e2>severe hypoalbuminemia without proteinuria</e2>, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

124	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, <e2>toxic hepatitis</e2>, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

125	"<e1>Methemoglobinemia</e1> is another common finding among patients receiving <e2>dapsone</e2> therapy, but rarely does it result in prominent symptoms other than transient pallor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

126	"<e1>Acetazolamide</e1> -accelerated anticonvulsant <e2>osteomalacia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

127	"<e1>Acetazolamide</e1> may have accelerated the development of <e2>osteomalacia</e2> by several mechanisms, including increased renal calcium excretion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

128	"<e1>Severe osteomalacia</e1> was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and <e2>acetazolamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

129	"<e1>Severe osteomalacia</e1> was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, <e2>phenobarbital</e2>, and acetazolamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

130	"<e1>Severe osteomalacia</e1> was present in two epileptic patients who were under long-term treatment with congeners of <e2>phenytoin</e2>, phenobarbital, and acetazolamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

131	"The delayed <e1>encephalopathy</e1> developed 9 and 22 months respectively after the first dose of intrathecal <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

132	"We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and <e1>hydrocephalus</e1> related to central nervous system prophylaxis by, in the first case intrathecally administered <e2>methotrexate</e2> and, in the second by intrathecally administered <e2>methotrexate</e2> and cranial irradiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

133	"We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and <e1>hydrocephalus</e1> related to central nervous system prophylaxis by, in the first case intrathecally administered <e2>methotrexate</e2> and, in the second by intrathecally administered <e2>methotrexate</e2> and cranial irradiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

134	"We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed <e1>leukoencephalopathy</e1> and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered <e2>methotrexate</e2> and, in the second by intrathecally administered <e2>methotrexate</e2> and cranial irradiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

135	"We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed <e1>leukoencephalopathy</e1> and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered <e2>methotrexate</e2> and, in the second by intrathecally administered <e2>methotrexate</e2> and cranial irradiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

136	"A retrospective study was conducted of 40 <e2>loperamide</e2> poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

137	"<e2>Loperamide</e2> poisoning in the dog."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

138	"a 67-year-old man with bipolar disorder developed a <e1>Creutzfeldt-Jakob like syndrome</e1> during <e2>lithium carbonate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

139	"<e1>Lithium</e1> -induced <e2>Creutzfeldt-Jakob syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

140	"<e1>Lithium</e1> neurotoxicity should be considered in <e2>Creutzfeldt-Jakob disease</e2> differential diagnosis, serial electroencephalograms being the most valuable."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

141	"<e2>Lithium</e2> neurotoxicity should be considered in Creutzfeldt-Jakob disease differential diagnosis, serial electroencephalograms being the most valuable."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

142	"Several cases of <e1>lithium</e1> -induced <e2>Creutzfeldt-Jakob syndrome</e2> have been reported to date; all of them were elderly patients and a half had "therapeutic" <e1>lithium</e1> serum levels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

143	"Several cases of <e1>lithium</e1> -induced <e2>Creutzfeldt-Jakob syndrome</e2> have been reported to date; all of them were elderly patients and a half had "therapeutic" <e1>lithium</e1> serum levels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

144	"A noninvasive method in the differential diagnosis of vecuronium-induced and <e1>magnesium</e1> -induced <e2>protracted neuromuscular block</e2> in a severely preeclamptic patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

145	"A noninvasive method in the differential diagnosis of <e1>vecuronium</e1> -induced and magnesium-induced <e2>protracted neuromuscular block</e2> in a severely preeclamptic patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

146	"The occurrence of <e1>neuromuscular blockade</e1> and the resulting potentiation of muscle relaxants during <e2>magnesium sulfate</e2> (MgSO4) administration is well known."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

147	"The occurrence of <e1>neuromuscular blockade</e1> and the resulting potentiation of muscle relaxants during magnesium sulfate (<e2>MgSO4</e2>) administration is well known."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

148	"The occurrence of neuromuscular blockade and the resulting <e1>potentiation of muscle relaxants</e1> during <e2>magnesium sulfate</e2> (MgSO4) administration is well known."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

149	"The occurrence of neuromuscular blockade and the resulting <e1>potentiation of muscle relaxants</e1> during magnesium sulfate (<e2>MgSO4</e2>) administration is well known."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

150	"We also describe a new, noninvasive method to assess <e1>magnesium</e1> -induced <e2>neuromuscular block</e2> when curariform muscle relaxant was given simultaneously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

151	"<e1>Hepatobiliary disorders</e1> associated with orally administered <e2>terbinafine</e2> have rarely been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

152	"<e1>Terbinafine</e1> -induced <e2>cholestatic liver disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

153	"We describe a case of prolonged <e1>terbinafine</e1> -induced <e2>cholestatic liver disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

154	"A patient with a large hydatid cyst of the left lobe of the liver developed <e1>metabolic acidosis</e1> following rather liberal use of <e2>cetrimide</e2> -chlorhexidine solution as a scolicidal agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

155	"A patient with a large hydatid cyst of the left lobe of the liver developed <e1>metabolic acidosis</e1> following rather liberal use of cetrimide-<e2>chlorhexidine</e2> solution as a scolicidal agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

156	"<e1>Metabolic acidosis</e1> induced by <e2>cetrimide</e2> -chlorhexidine solution in hydatid cyst surgery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

157	"<e1>Metabolic acidosis</e1> induced by cetrimide-<e2>chlorhexidine</e2> solution in hydatid cyst surgery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

158	"An unusual case of <e2>Ecstasy</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

159	"We describe a case of <e1>poisoning</e1> with <e2>3,4-methylenedioxymet-amphetamine Ecstasy</e2> that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

160	"However, dermatologists should be cautious about a <e1>photosensitivity</e1> reaction induced by <e2>mequitazine</e2> or other phenothiazine-derivative drugs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

161	"In addition, an immediate <e1>erythematous macule</e1> was observed on the photopatch test site of <e2>mequitazine</e2> directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

162	"In addition, an <e1>immediate erythema</e1>tous macule was observed on the photopatch test site of <e2>mequitazine</e2> directly after UV exposure which was similar to the <e1>immediate erythema</e1> noted in chlorpromazine photoallergy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

163	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, <e2>cross-reaction to promethazine</e2>, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

164	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, <e2>cross-reaction to promethazine</e2>, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

165	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to <e2>promethazine</e2>, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

166	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, <e2>decreased MED to both UVA and UVB</e2>, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

167	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, <e2>decreased MED to both UVA and UVB</e2>, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

168	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to <e1>promethazine</e1>, <e2>decreased MED to both UVA and UVB</e2>, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

169	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate <e2>erythema</e2> reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

170	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate <e2>erythema</e2> reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

171	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate <e1>erythema</e1> reaction, cross-reaction to <e2>promethazine</e2>, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

172	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and <e2>persistence of the photosensitivity</e2> over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

173	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and <e2>persistence of the photosensitivity</e2> over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

174	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to <e1>promethazine</e1>, decreased MED to both UVA and UVB, and <e2>persistence of the photosensitivity</e2> over a 3-year follow-up period after discontinuation of the mequitazine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

175	"Mequitazine seemed to play a part similar to chlorpromazine, and absence of <e1>mequitazine</e1> -induced <e2>photosensitivity</e2> may be due to a relatively low dosage of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

176	"Two cases of <e1>mequitazine</e1> -induced <e2>photosensitivity reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

177	"We experienced 2 cases of <e1>mequitazine</e1> -induced <e2>photosensitivity reaction</e2> in patients who took <e1>mequitazine</e1> for their dermatologic problems."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

178	"We experienced 2 cases of <e1>mequitazine</e1> -induced <e2>photosensitivity reaction</e2> in patients who took <e1>mequitazine</e1> for their dermatologic problems."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

179	"<e1>Keratitis</e1> in <e2>methamphetamine</e2> abusers."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

180	"<e1>Methamphetamine</e1>'s extensive physiologic effects, inconsistent street purity, and multiple routes of administration offer many possibilities for <e2>injury to the cornea</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

181	"Potential causes of methamphetamine-related <e1>keratitis</e1> can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or "cutting" agents such as <e2>lidocaine</e2> and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

182	"Potential causes of <e1>methamphetamine</e1> -related <e2>keratitis</e2> can be divided into four categories resulting from (a) direct pharmacologic and physical effects of <e1>methamphetamine</e1>; (b) the toxic effects of diluting or "cutting" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

183	"Potential causes of methamphetamine-related <e1>keratitis</e1> can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or "cutting" agents such as lidocaine and <e2>quinine</e2>; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

184	"Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the <e1>toxic effects</e1> of diluting or "cutting" agents such as <e2>lidocaine</e2> and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

185	"Potential causes of <e1>methamphetamine</e1> -related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of <e1>methamphetamine</e1>; (b) the <e2>toxic effects</e2> of diluting or "cutting" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

186	"Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the <e1>toxic effects</e1> of diluting or "cutting" agents such as lidocaine and <e2>quinine</e2>; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

187	"The increasing prevalence of <e1>methamphetamine</e1> abuse and the severity of the associated ulcers should alert ophthalmologists to the problem of <e1>methamphetamine</e1> -related <e2>keratitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

188	"The increasing prevalence of <e1>methamphetamine</e1> abuse and the severity of the associated <e2>ulcers</e2> should alert ophthalmologists to the problem of <e1>methamphetamine</e1> -related keratitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

189	"We report four cases of <e1>severe corneal ulceration</e1> in <e2>methamphetamine</e2> abusers."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

190	"BACKGROUND: <e1>Methotrexate</e1> (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or <e2>cirrhosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

191	"BACKGROUND: Methotrexate (<e1>MTX</e1>) may induce liver damage, which in some psoriatics will lead to fibrosis or <e2>cirrhosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

192	"BACKGROUND: <e1>Methotrexate</e1> (MTX) may induce liver damage, which in some psoriatics will lead to <e2>fibrosis</e2> or cirrhosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

193	"BACKGROUND: Methotrexate (<e1>MTX</e1>) may induce liver damage, which in some psoriatics will lead to <e2>fibrosis</e2> or cirrhosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

194	"BACKGROUND: <e1>Methotrexate</e1> (MTX) may induce <e2>liver damage</e2>, which in some psoriatics will lead to fibrosis or cirrhosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

195	"BACKGROUND: Methotrexate (<e1>MTX</e1>) may induce <e2>liver damage</e2>, which in some psoriatics will lead to fibrosis or cirrhosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

196	"CONCLUSIONS: This study confirmed that in most patients <e1>MTX</e1> -induced <e2>liver cirrhosis</e2> is not aggressive."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

197	"However, continued low-dose <e1>MTX</e1> led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and <e2>death</e2> in 1 of our patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

198	"However, continued low-dose <e1>MTX</e1> led, in spite of normal liver tests, 8 years after the last biopsy to <e2>liver failure</e2> and death in 1 of our patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

199	"<e1>Methotrexate</e1> -induced <e2>liver cirrhosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

200	"Studies performed 10 years ago on 25 patients with <e1>MTX</e1> -induced liver <e2>cirrhosis</e2> indicated that this type of <e2>cirrhosis</e2> was not of an aggressive nature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

201	"Studies performed 10 years ago on 25 patients with <e1>MTX</e1> -induced <e2>liver cirrhosis</e2> indicated that this type of cirrhosis was not of an aggressive nature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

202	"After therapy for diabetic coma with insulin (containing the preservative <e1>cresol</e1>) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a <e2>high fever</e2> and respiratory and metabolic acidosis and lost consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

203	"After therapy for diabetic coma with <e1>insulin</e1> (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a <e2>high fever</e2> and respiratory and metabolic acidosis and lost consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

204	"After therapy for diabetic coma with insulin (containing the preservative <e1>cresol</e1>) and electrolyte solutions was started, the patient complained of <e2>increasing myalgia</e2>, developed a high fever and respiratory and metabolic acidosis and lost consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

205	"After therapy for diabetic coma with <e1>insulin</e1> (containing the preservative cresol) and electrolyte solutions was started, the patient complained of <e2>increasing myalgia</e2>, developed a high fever and respiratory and metabolic acidosis and lost consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

206	"After therapy for diabetic coma with insulin (containing the preservative <e1>cresol</e1>) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and <e2>lost consciousness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

207	"After therapy for diabetic coma with <e1>insulin</e1> (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and <e2>lost consciousness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

208	"After therapy for diabetic coma with insulin (containing the preservative <e1>cresol</e1>) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and <e2>respiratory and metabolic acidosis</e2> and lost consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

209	"After therapy for diabetic coma with <e1>insulin</e1> (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and <e2>respiratory and metabolic acidosis</e2> and lost consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

210	"However, other factors or drugs (e.g. <e1>cresol</e1>) are thought to induce <e2>MH</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

211	"This case supports the assessment that <e1>MH</e1> and diabetes are associated diseases and that <e2>cresol</e2> could possibly trigger <e1>MH</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

212	"The use of <e1>beclomethasone diproprionate</e1> inhaler complicated by the development of an <e2>eosinophilic pneumonia reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

213	"<e1>Fatal intravascular autoimmune hemolytic anemia</e1> after <e2>fludarabine</e2> treatment for chronic lymphocytic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

214	"Physicians should be aware of the risk of severe <e1>AIHA</e1> in CLL patients with a history of <e1>AIHA</e1> or positivation of the DAT during previous <e2>fludarabine</e2> administration, or in case of secondary fixation of complement to the red cell membrane occurring during <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

215	"Physicians should be aware of the risk of severe <e1>AIHA</e1> in CLL patients with a history of <e1>AIHA</e1> or positivation of the DAT during previous <e2>fludarabine</e2> administration, or in case of secondary fixation of complement to the red cell membrane occurring during <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

216	"Physicians should be aware of the risk of severe <e1>AIHA</e1> in CLL patients with a history of <e1>AIHA</e1> or positivation of the DAT during previous <e2>fludarabine</e2> administration, or in case of secondary fixation of complement to the red cell membrane occurring during <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

217	"Physicians should be aware of the risk of severe <e1>AIHA</e1> in CLL patients with a history of <e1>AIHA</e1> or positivation of the DAT during previous <e2>fludarabine</e2> administration, or in case of secondary fixation of complement to the red cell membrane occurring during <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

218	"Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or <e1>positivation of the DAT</e1> during previous <e2>fludarabine</e2> administration, or in case of secondary fixation of complement to the red cell membrane occurring during <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

219	"Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or <e1>positivation of the DAT</e1> during previous <e2>fludarabine</e2> administration, or in case of secondary fixation of complement to the red cell membrane occurring during <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

220	"The occurrence of severe <e1>AIHA</e1> in CLL patients treated with <e2>fludarabine</e2> has been reported by several authors."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

221	"We report the case of a patient with chronic lymphocytic leukemia (CLL) who developed fatal intravascular autoimmune hemolytic anemia (<e1>AIHA</e1>) after <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

222	"We report the case of a patient with chronic lymphocytic leukemia (CLL) who developed <e1>fatal intravascular autoimmune hemolytic anemia</e1> (AIHA) after <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

223	"When the patient was treated again with <e1>fludarabine</e1> nine months later, the <e2>DAT became positive with anti-IgG and anti-C3d antiglobulins</e2> after the second course of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

224	"She had just finished a 3-week course of intravenous <e1>tobramycin</e1> for bronchiectasis and had an elevated serum <e1>tobramycin</e1> trough level 1 week before the onset of <e2>tetany</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

225	"<e1>Tetany</e1> in a child with AIDS receiving intravenous <e2>tobramycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

226	"This pattern is suggestive of <e1>renal toxicity</e1> due to <e2>tobramycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

227	"CONCLUSIONS: In our reported case, a local hyperproduction of TNF-alpha from macrophages that was induced by the injected <e1>insulin</e1> could explain the <e2>dedifferentiation of the adipocytes</e2> of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

228	"CONCLUSIONS: In our reported case, a local <e1>hyperproduction of TNF-alpha</e1> from macrophages that was induced by the injected <e2>insulin</e2> could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

229	"<e1>Insulin</e1> -induced <e2>lipoatrophy</e2> in type I diabetes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

230	"OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the <e1>insulin</e1> -induced <e2>lipoatrophies</e2> of a diabetic patient who presented extensive lesions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

231	"<e1>Erosion of psoriatic plaques</e1>: an early sign of <e2>methotrexate</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

232	"Erosion of psoriatic plaques: an early sign of <e2>methotrexate</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

233	"<e1>Methotrexate</e1> is an effective but <e2>potentially toxic</e2> treatment for psoriasis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

234	"Painful erosion of psoriatic plaques is a less common sign of <e1>methotrexate</e1> toxicity that may precede evidence of <e2>bone marrow suppression</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

235	"Painful erosion of psoriatic plaques is a less common sign of <e2>methotrexate</e2> toxicity that may precede evidence of bone marrow suppression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

236	"<e1>Painful erosion of psoriatic plaques</e1> is a less common sign of <e2>methotrexate</e2> toxicity that may precede evidence of bone marrow suppression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

237	"We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of <e2>methotrexate</e2> toxicity and review the literature, emphasizing the risk factors associated with this manifestation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

238	"We describe two patients in whom <e1>painful erosions of their psoriasis</e1> developed as the presenting sign of <e2>methotrexate</e2> toxicity and review the literature, emphasizing the risk factors associated with this manifestation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

239	"Well-known signs of <e1>methotrexate</e1> toxicity include <e2>bone marrow suppression</e2> and oral and gastrointestinal ulceration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

240	"Well-known signs of <e2>methotrexate</e2> toxicity include bone marrow suppression and oral and gastrointestinal ulceration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

241	"Well-known signs of <e1>methotrexate</e1> toxicity include bone marrow suppression and <e2>oral and gastrointestinal ulceration</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

242	"After treatment with <e1>cimetidine</e1>, there was a rapid deterioration with <e2>decreased oxygen saturation and arterial PO2</e2> values."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

243	"Caution with use of <e1>cimetidine</e1> in tolazoline induced <e2>upper gastrointestinal bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

244	"Caution with use of cimetidine in <e1>tolazoline</e1> induced <e2>upper gastrointestinal bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

245	"However, given the clinically significant result to the interaction between tolazoline and <e1>cimetidine</e1> we report, the use of <e1>cimetidine</e1> in tolazoline induced <e2>upper gastrointestinal hemorrhage</e2> should deserve more attention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

246	"However, given the clinically significant result to the interaction between tolazoline and <e1>cimetidine</e1> we report, the use of <e1>cimetidine</e1> in tolazoline induced <e2>upper gastrointestinal hemorrhage</e2> should deserve more attention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

247	"However, given the clinically significant result to the interaction between <e1>tolazoline</e1> and cimetidine we report, the use of cimetidine in <e1>tolazoline</e1> induced <e2>upper gastrointestinal hemorrhage</e2> should deserve more attention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

248	"However, given the clinically significant result to the interaction between <e1>tolazoline</e1> and cimetidine we report, the use of cimetidine in <e1>tolazoline</e1> induced <e2>upper gastrointestinal hemorrhage</e2> should deserve more attention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

249	"Hypoxemia improved during continuous <e1>tolazoline</e1> infusion, but <e2>gastrointestinal bleeding</e2> occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

250	"Zolpidem (<e1>Ambien</e1>), a relatively new nonbenzodiazepine sedative-hypnotic, was involved in the <e2>death</e2> of a 39-year-old obese male who was being treated for depression and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

251	"<e1>Zolpidem</e1> (Ambien), a relatively new nonbenzodiazepine sedative-hypnotic, was involved in the <e2>death</e2> of a 39-year-old obese male who was being treated for depression and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

252	"Zolpidem tissue concentrations in a multiple drug related <e1>death</e1> involving <e2>Ambien</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

253	"<e1>Zolpidem</e1> tissue concentrations in a multiple drug related <e2>death</e2> involving Ambien."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

254	"Acute <e2>nitrite</e2> toxicity results from industrial exposure, accidental ingestion (e.g., abuse of organic <e2>nitrite</e2>s as an aphrodisiac, especially in the male homosexual population), and suicidal ingestion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

255	"Infants are particularly susceptible to chronic <e1>nitrate</e1> -induced <e2>methemoglobinemia</e2> because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

256	"Acute <e2>esmolol</e2> toxicity may be self-limiting because of its extremely short half-life."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

257	"After induction of general anesthesia and administration of a standard dose of intravenous <e1>esmolol hydrochloride</e1>, her cardiac rhythm progressed to <e2>asystole</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

258	"<e1>Cardiac arrest</e1> after <e2>esmolol</e2> administration: a review of acute beta-blocker toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

259	"<e1>Atenolol</e1> induced <e2>memory impairment</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

260	"His <e1>impaired memory</e1> was found to be due to the <e2>atenolol</e2> he was on and he made a complete recovery on withdrawing the beta-blocker."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

261	"A potential role for renal and hepatic impairment in the observed protracted course of <e1>amiodarone</e1> -induced <e2>thyrotoxicosis</e2> is suggested."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

262	"Failure of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted <e1>amiodarone</e1> -induced <e2>thyroiditis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

263	"We report a case of <e1>amiodarone</e1> -induced <e2>thyrotoxicosis</e2> of protracted duration, unresponsive to conventional thionamide therapy, with therapy limited by severe adverse drug reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

264	"<e1>Psychotic disorder</e1> associated with <e2>isoniazid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

265	"We evaluated a patient who developed a <e1>psychotic disorder</e1> after 4 months of <e2>isoniazid</e2> prophylaxis for a positive tuberculosis tine test."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

266	"A case report is presented concerning the administration of ketanserin in the treatment of <e1>pulmonary vasoconstriction</e1> and right ventricular failure following the infusion of <e2>protamine</e2> in a patient undergoing coronary artery bypass surgery and mitral valve replacement."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

267	"A case report is presented concerning the administration of ketanserin in the treatment of pulmonary vasoconstriction and <e1>right ventricular failure</e1> following the infusion of <e2>protamine</e2> in a patient undergoing coronary artery bypass surgery and mitral valve replacement."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

268	"Ketanserin in the treatment of <e1>protamine</e1> -induced <e2>pulmonary hypertension</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

269	"The reversal of heparin by <e1>protamine</e1> may cause severe hemodynamic deterioration, characterized by systemic hypotension, pulmonary hypertension, and <e2>bronchoconstriction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

270	"The reversal of heparin by <e1>protamine</e1> may cause severe hemodynamic deterioration, characterized by systemic hypotension, <e2>pulmonary hypertension</e2>, and bronchoconstriction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

271	"The reversal of heparin by <e1>protamine</e1> may cause <e2>severe hemodynamic deterioration</e2>, characterized by systemic hypotension, pulmonary hypertension, and bronchoconstriction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

272	"The reversal of heparin by <e1>protamine</e1> may cause severe hemodynamic deterioration, characterized by <e2>systemic hypotension</e2>, pulmonary hypertension, and bronchoconstriction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

273	"A drug addict with staphylococcal endocarditis treated with <e1>methicillin</e1>, who developed massive proteinuria and <e2>acute nephritic syndrome</e2> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

274	"A drug addict with staphylococcal endocarditis treated with <e1>methicillin</e1>, who developed <e2>massive proteinuria</e2> and acute nephritic syndrome is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

275	"<e1>Focal glomerulonephritis</e1> and interstitial nephritis in <e2>methicillin</e2> -treated, heroin-related infective endocarditis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

276	"Focal glomerulonephritis and <e1>interstitial nephritis</e1> in <e2>methicillin</e2> -treated, heroin-related infective endocarditis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

277	"METHODS/RESULTS: This paper presents a new case of <e1>rifabutin</e1> <e2>uveitis</e2> and a review of the various published reports to date."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

278	"over the past 3 years there have been several reports of <e1>uveitis</e1> associated with <e2>rifabutin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

279	"<e1>Uveitis</e1> associated with <e2>rifabutin</e2> therapy: a clinical alert."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

280	"CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a <e1>large cerebral infarction</e1> during <e2>praziquantel</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

281	"<e1>Large cerebral infarction</e1> during <e2>praziquantel</e2> therapy in neurocysticercosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

282	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., <e2>diarrhea</e2>, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

283	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., <e2>diarrhea</e2>, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

284	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, <e2>mucositis</e2>, myelosuppression, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

285	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, <e2>mucositis</e2>, myelosuppression, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

286	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, <e2>myelosuppression</e2>, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

287	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, <e2>myelosuppression</e2>, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

288	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, <e2>neurotoxicity</e2>) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

289	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, <e2>neurotoxicity</e2>) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

290	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, <e2>stomatitis</e2>, mucositis, myelosuppression, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

291	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, <e2>stomatitis</e2>, mucositis, myelosuppression, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

292	"Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing <e1>severe adverse reactions</e1> to <e2>5-fluorouracil</e2> -based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

293	"PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially <e1>lethal adverse reactions</e1> following <e2>5-fluorouracil</e2> (5-FU)-based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

294	"PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially <e1>lethal adverse reactions</e1> following 5-fluorouracil (<e2>5-FU</e2>)-based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

295	"The principle treatment for DPD-deficient patients with severe acute <e1>5-FU</e1> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e1>5-FU</e1> -induced neurologic symptoms such as encephalopathy and <e2>coma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

296	"The principle treatment for DPD-deficient patients with severe acute <e1>5-FU</e1> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e1>5-FU</e1> -induced neurologic symptoms such as encephalopathy and <e2>coma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

297	"The principle treatment for DPD-deficient patients with severe acute <e1>5-FU</e1> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e1>5-FU</e1> -induced neurologic symptoms such as <e2>encephalopathy</e2> and coma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

298	"The principle treatment for DPD-deficient patients with severe acute <e1>5-FU</e1> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e1>5-FU</e1> -induced neurologic symptoms such as <e2>encephalopathy</e2> and coma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

299	"The principle treatment for DPD-deficient patients with severe acute <e1>5-FU</e1> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e1>5-FU</e1> -induced <e2>neurologic symptoms</e2> such as encephalopathy and coma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

300	"The principle treatment for DPD-deficient patients with severe acute <e1>5-FU</e1> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e1>5-FU</e1> -induced <e2>neurologic symptoms</e2> such as encephalopathy and coma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

301	"The principle treatment for DPD-deficient patients with severe acute <e2>5-FU</e2> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e2>5-FU</e2> -induced neurologic symptoms such as encephalopathy and coma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

302	"The principle treatment for DPD-deficient patients with severe acute <e2>5-FU</e2> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e2>5-FU</e2> -induced neurologic symptoms such as encephalopathy and coma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

303	"A 49-year-old man with Crohn's disease treated with prednisone and mesalamine (<e1>5-ASA</e1>) developed worsening respiratory distress and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

304	"A 49-year-old man with Crohn's disease treated with prednisone and <e1>mesalamine</e1> (5-ASA) developed worsening respiratory distress and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

305	"A 49-year-old man with Crohn's disease treated with <e1>prednisone</e1> and mesalamine (5-ASA) developed worsening respiratory distress and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

306	"A 49-year-old man with Crohn's disease treated with prednisone and mesalamine (<e1>5-ASA</e1>) developed <e2>worsening respiratory distress</e2> and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

307	"A 49-year-old man with Crohn's disease treated with prednisone and <e1>mesalamine</e1> (5-ASA) developed <e2>worsening respiratory distress</e2> and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

308	"A 49-year-old man with Crohn's disease treated with <e1>prednisone</e1> and mesalamine (5-ASA) developed <e2>worsening respiratory distress</e2> and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

309	"<e1>Mesalamine</e1> -induced <e2>hypersensitivity pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

310	"<e1>Mesalamine</e1> may cause <e2>hypersensitivity pneumonitis</e2> in patients with Crohn's disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

311	"Immunosuppression elicited by the extensive administration of <e1>prednisolone</e1> was suspected for the initiation of the generalized <e2>mite infestation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

312	"BACKGROUND: <e1>Colchicine</e1> has a known <e2>adverse effect on wound healing</e2> through its inhibitory effect on tubulin-dependent cell functions and through collagenase activation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

313	"BACKGROUND: <e1>Colchicine</e1> has a known adverse effect on wound healing through its inhibitory effect on tubulin-dependent cell functions and through <e2>collagenase activation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

314	"CONCLUSION: The findings in these two patients suggest that <e1>colchicine</e1> may <e2>delay corneal wound healing</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

315	"<e1>Delay of corneal wound healing</e1> in patients treated with <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

316	"The authors report on two patients with <e1>corneal ulcers refractory to conventional treatment</e1> while the patients were undergoing oral <e2>colchicine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

317	"The authors suggest that in patients with <e1>corneal ulcers refractory to conventional treatment</e1> who are receiving <e2>colchicine</e2>, cessation of <e2>colchicine</e2> therapy should be considered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

318	"<e1>Fulminant hepatic failure</e1> associated with <e2>bicalutamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

319	"A 17-year-old female patient who had been taking oral <e1>minocycline</e1> (50 mg twice daily) for 3 weeks for acne developed an <e2>eruption</e2> that progressed to an exfoliative dermatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

320	"A 17-year-old female patient who had been taking oral <e1>minocycline</e1> (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an <e2>exfoliative dermatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

321	"Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and <e1>dermatitis</e1>: a severe adverse reaction to <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

322	"Fever, lymphadenopathy, <e1>eosinophilia</e1>, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

323	"<e1>Fever</e1>, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

324	"Fever, lymphadenopathy, eosinophilia, lymphocytosis, <e1>hepatitis</e1>, and dermatitis: a severe adverse reaction to <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

325	"Fever, <e1>lymphadenopathy</e1>, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

326	"Fever, lymphadenopathy, eosinophilia, <e1>lymphocytosis</e1>, hepatitis, and dermatitis: a severe adverse reaction to <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

327	"This severe illness was likely caused by <e1>minocycline</e1>, and we speculate that <e1>minocycline</e1> may have acted as a superantigen, causing <e2>lymphocyte over-activation</e2> and massive cytokine release."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

328	"This severe illness was likely caused by <e1>minocycline</e1>, and we speculate that <e1>minocycline</e1> may have acted as a superantigen, causing lymphocyte over-activation and <e2>massive cytokine release</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

329	"This <e1>severe illness</e1> was likely caused by <e2>minocycline</e2>, and we speculate that <e2>minocycline</e2> may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

330	"<e1>Delayed hypersensitivity</e1> to <e2>flurbiprofen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

331	"<e1>Eye movement disorders</e1> in bone marrow transplant patients on <e2>cyclosporin</e2> and ganciclovir."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

332	"<e1>Eye movement disorders</e1> in bone marrow transplant patients on cyclosporin and <e2>ganciclovir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

333	"One patient had <e1>MRI T2 abnormalities</e1> compatible with <e2>cyclosporin</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

334	"One patient had MRI T2 abnormalities compatible with <e1>cyclosporin</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

335	"We postulate that <e1>cyclosporin</e1>, possibly together with ganciclovir, can produce transient brain stem or neuromuscular dysfunction with <e2>eye movement abnormality</e2> in occasional patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

336	"We postulate that cyclosporin, possibly together with <e1>ganciclovir</e1>, can produce transient brain stem or neuromuscular dysfunction with <e2>eye movement abnormality</e2> in occasional patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

337	"We postulate that <e1>cyclosporin</e1>, possibly together with ganciclovir, can produce <e2>transient brain stem or neuromuscular dysfunction</e2> with eye movement abnormality in occasional patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

338	"We postulate that cyclosporin, possibly together with <e1>ganciclovir</e1>, can produce <e2>transient brain stem or neuromuscular dysfunction</e2> with eye movement abnormality in occasional patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

339	"CONCLUSION: While <e1>thrombosis</e1> has been reported with <e2>GnRH-a</e2> therapy in men with prostate cancer, its association with treatment in this benign case may have been a consequence of the massive tumor size."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

340	"The possible effects of <e1>tamoxifen</e1> upon the uterus are discussed in this article, in view of reports of <e1>tamoxifen</e1> associated with <e2>endometrial carcinoma</e2> and endometriosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

341	"The possible effects of <e1>tamoxifen</e1> upon the uterus are discussed in this article, in view of reports of <e1>tamoxifen</e1> associated with endometrial carcinoma and <e2>endometriosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

342	"Case study: <e1>adverse response</e1> to <e2>clonidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

343	"Four cases of <e1>adverse experiences</e1> with <e2>clonidine</e2> are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

344	"In one instance a systemic hypoglycemic reaction resulting in head trauma and <e1>confusion</e1> ended in an emegency hospital admission following the substitution of <e2>acetohexamide</e2> for acetazolamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

345	"In one instance a systemic hypoglycemic reaction resulting in <e1>head trauma</e1> and confusion ended in an emegency hospital admission following the substitution of <e2>acetohexamide</e2> for acetazolamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

346	"In one instance a <e1>systemic hypoglycemic reaction</e1> resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of <e2>acetohexamide</e2> for acetazolamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

347	"Discontinuation of the <e1>itraconazole</e1> caused resolution of the <e2>drug eruption</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

348	"Primary cutaneous coccidioidomycosis and subsequent <e1>drug eruption</e1> to <e2>itraconazole</e2> in a dog."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

349	"<e1>Primary cutaneous coccidioidomycosis</e1> and subsequent drug eruption to <e2>itraconazole</e2> in a dog."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

350	"Its overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a <e1>potentially fatal symptom</e1> complex referred to as "<e2>retinoic acid</e2> syndrome." This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

351	"Its overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as "<e2>retinoic acid</e2> syndrome." This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

352	"Its overall <e1>toxicity</e1> is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as "<e2>retinoic acid</e2> syndrome." This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

353	"Eleven days after initiation of therapy with <e1>amiodarone</e1>, the patient experienced syncope and was noted to have recurrent episodes of <e2>polymorphous ventricular tachycardia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

354	"Eleven days after initiation of therapy with <e1>amiodarone</e1>, the patient experienced <e2>syncope</e2> and was noted to have recurrent episodes of polymorphous ventricular tachycardia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

355	"<e1>Nonsustained polymorphous ventricular tachycardia</e1> during <e2>amiodarone</e2> therapy for atrial fibrillation complicating cardiomyopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

356	"The probable <e1>proarrhythmic</e1> action of <e2>amiodarone</e2>, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

357	"<e1>Acute asthma</e1> associated with sustained-release <e2>verapamil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

358	"Although dyspnea associated with <e1>verapamil</e1> administration has been reported, this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an <e2>acute asthma</e2> attack following sustained-release <e1>verapamil</e1> administration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

359	"Although <e1>dyspnea</e1> associated with <e2>verapamil</e2> administration has been reported, this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an acute asthma attack following sustained-release <e2>verapamil</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

360	"CONCLUSIONS: Sustained-release <e1>verapamil</e1> is thought to be the cause of the <e2>asthma attack</e2> in this patient because she was not taking any other preparations; the symptoms started with the administration of sustained-release <e1>verapamil</e1> and were relieved after its discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

361	"CONCLUSIONS: Sustained-release <e1>verapamil</e1> is thought to be the cause of the <e2>asthma attack</e2> in this patient because she was not taking any other preparations; the symptoms started with the administration of sustained-release <e1>verapamil</e1> and were relieved after its discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

362	"OBJECTIVE: To describe a patient with asymptomatic bronchial asthma and hypertension who developed an <e1>acute asthma</e1> attack after receiving sustained-release <e2>verapamil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

363	"She continued taking <e1>verapamil</e1> for 6 months, then, on her own, stopped all medications including the sustained-release <e1>verapamil</e1>, and her <e2>asthma</e2> symptoms disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

364	"<e2>Cephalexin</e2> rash in infectious mononucleosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

365	"The <e2>ampicillin</e2> rash occurring in cases of infectious mononucleosis is well documented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

366	"The case of a patient with infectious mononucleosis treated with <e1>cephalexin</e1> who later showed a <e2>rash</e2> is presented and the previous literature is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

367	"The <e1>rash</e1> seen in this patient, who was treated with <e2>cephalexin</e2>, may be similar to the <e1>rash</e1> seen with ampicillin treatment of patients with infectious mononucleosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

368	"The <e1>rash</e1> seen in this patient, who was treated with cephalexin, may be similar to the <e1>rash</e1> seen with <e2>ampicillin</e2> treatment of patients with infectious mononucleosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

369	"A possible case of <e1>carbamazepine</e1> induced <e2>pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

370	"The authors report a case of acute <e1>pancreatitis</e1> (AP) occurring in a patient under treatment with <e2>carbamazepine</e2> (CBZ) for post-traumatic petit mal epilepsy, and review the current literature of drug-induced AP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

371	"The authors report a case of acute <e1>pancreatitis</e1> (AP) occurring in a patient under treatment with carbamazepine (<e2>CBZ</e2>) for post-traumatic petit mal epilepsy, and review the current literature of drug-induced AP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

372	"The evidence of high plasmatic levels of <e1>CBZ</e1> and the absence of other aetiologic factors lead the authors to conclude that the overdose of <e1>CBZ</e1> could have represented the precipitating of the episode of <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

373	"The evidence of high plasmatic levels of <e1>CBZ</e1> and the absence of other aetiologic factors lead the authors to conclude that the overdose of <e1>CBZ</e1> could have represented the precipitating of the episode of <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

374	"Although risk factors for <e1>MTX</e1> -induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of <e1>MTX</e1> <e2>pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

375	"Although risk factors for <e1>MTX</e1> -induced <e2>pulmonary toxicity</e2> are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of <e1>MTX</e1> pneumonitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

376	"<e1>Methotrexate</e1> -induced <e2>pneumonitis</e2> in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

377	"On the other hand, <e1>MTX</e1> -induced <e2>pneumonitis</e2> seems to be very rare in psoriatic arthritis (PsA)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

378	"Our review of 194 RA patients and 38 PsA patients receiving <e1>MTX</e1> has identified four RA patients and one PsA patient with <e1>MTX</e1> -induced <e2>pneumonitis</e2>, giving a prevalence of 2.1% and 0.03%, respectively."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

379	"<e1>Pneumonitis</e1> is emerging as one of the most unpredictable and potentially serious, adverse effects of treatment with <e2>MTX</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

380	"The presence of a lymphocyte alveolitis with a predominance of CD4+ T cells in 3 RA patients and CD8+ T cells with a concomitant increase in neutrophils in another case suggests that immunologically mediated reactions may be one damage mechanism in <e1>MTX</e1> -induced <e2>pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

381	"A retrospective epidemiological study of deaths from <e1>hepatic angiosarcoma</e1> (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes (vinyl chloride, 'Thorotrast', and <e2>inorganic arsenic</e2>) and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

382	"A retrospective epidemiological study of deaths from <e1>hepatic angiosarcoma</e1> (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes (vinyl chloride, '<e2>Thorotrast</e2>', and inorganic arsenic) and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

383	"A retrospective epidemiological study of deaths from <e1>hepatic angiosarcoma</e1> (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes (<e2>vinyl chloride</e2>, 'Thorotrast', and inorganic arsenic) and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

384	"Recent studies have shown that under experimental conditions <e1>ferrous sulfate</e1> may <e2>reduce the gastrointestinal absorption of orally administered levothyroxine sodium</e2> in patients with primary hypothyroidism."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

385	"We describe a patient who became <e1>hypothyroid</e1> while taking <e2>ferrous sulfate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

386	"However, as the use of <e1>hepatitis B vaccination</e1> is growing, adverse side effects, including <e2>mental nerve neuropathy</e2>, should be observed with an increased frequency."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

387	"<e1>Mental nerve neuropathy</e1> as a result of <e2>hepatitis B vaccination</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

388	"Although its side effects are few, <e1>tamoxifen</e1> increases the incidence of <e2>proliferative lesions of the endometrium</e2>, which theoretically should be preventable with progestational agents."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

389	"CASES: Two postmenopausal women treated with <e1>tamoxifen</e1> and progestational agents for breast carcinoma developed uterine enlargement and <e2>intermittent spotting</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

390	"CASES: Two postmenopausal women treated with <e1>tamoxifen</e1> and progestational agents for breast carcinoma developed <e2>uterine enlargement</e2> and intermittent spotting."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

391	"CONCLUSIONS: The value of multihormonal therapy in breast <e1>carcinoma</e1> is not established, and the addition of progestogens to <e2>tamoxifen</e2> may not reduce of developing endometrial lesions, including <e1>carcinoma</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

392	"CONCLUSIONS: The value of multihormonal therapy in breast carcinoma is not established, and the addition of progestogens to <e1>tamoxifen</e1> may not reduce of developing <e2>endometrial lesions</e2>, including carcinoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

393	"<e1>Bleomycin</e1> and cyclophosphamide toxicity simulating <e2>metastatic nodules</e2> to the lungs in childhood cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

394	"Bleomycin and <e1>cyclophosphamide</e1> toxicity simulating <e2>metastatic nodules</e2> to the lungs in childhood cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

395	"Thoracoscopic biopsy to confirm metastasis revealed instead <e1>fibrotic lesions</e1> apparently attributable to <e2>bleomycin</e2> or cyclophosphamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

396	"Thoracoscopic biopsy to confirm metastasis revealed instead <e1>fibrotic lesions</e1> apparently attributable to bleomycin or <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

397	"An elderly man with <e1>procainamide hydrochloride</e1> -induced <e2>lupus syndrome</e2> had a circulating anticoagulant against factor XI and a biologic false-positive (BFP) test result for syphilis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

398	"Circulating anticoagulant in the <e1>procainamide</e1> -induced <e2>lupus syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

399	"Clinical signs of <e1>hypermagnesemia</e1> are an uncommon complication following oral administration of <e2>magnesium sulfate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

400	"Establishment of diuresis with fluids and IV administration of calcium may provide successful treatment of <e2>magnesium</e2> toxicosis in horses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

401	"<e2>Magnesium</e2> toxicosis in two horses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

402	"Overdose of <e1>magnesium</e1> sulfate in combination with renal insufficiency, hypocalcemia, or compromise of intestinal integrity may predispose horses to <e1>magnesium</e1> toxicosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

403	"Overdose of <e1>magnesium sulfate</e1> in combination with renal insufficiency, hypocalcemia, or compromise of intestinal integrity may predispose horses to <e2>magnesium toxicosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

404	"CASE SUMMARIES: In each case, the patients were treated over 5 years with <e1>lovastatin</e1> and developed <e2>rhabdomyolysis</e2> that coincided with the completion of a prescribed regimen of a newer macrolide antibiotic."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

405	"CONCLUSIONS: The risk of drug-induced <e1>rhabdomyolysis</e1> due to the potential interaction between lovastatin and <e2>azithromycin</e2> or clarithromycin should be considered before the concomitant use of these agents."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

406	"CONCLUSIONS: The risk of drug-induced <e1>rhabdomyolysis</e1> due to the potential interaction between lovastatin and azithromycin or <e2>clarithromycin</e2> should be considered before the concomitant use of these agents."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

407	"CONCLUSIONS: The risk of drug-induced <e1>rhabdomyolysis</e1> due to the potential interaction between <e2>lovastatin</e2> and azithromycin or clarithromycin should be considered before the concomitant use of these agents."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

408	"DISCUSSION: Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure Several drugs have been associated with <e1>rhabdomyolysis</e1>, including <e2>lovastatin</e2>, a hydroxymethylglutaryl-coenzyme A reductase inhibitor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

409	"<e1>Erythromycin</e1> is a macrolide antibiotic that may increase the risk of lovastatin-induced <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

410	"Erythromycin is a macrolide antibiotic that may increase the risk of <e1>lovastatin</e1> -induced <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

411	"Lovastatin-induced <e1>rhabdomyolysis</e1> possibly associated with clarithromycin and <e2>azithromycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

412	"Lovastatin-induced <e1>rhabdomyolysis</e1> possibly associated with <e2>clarithromycin</e2> and azithromycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

413	"<e1>Lovastatin</e1> -induced <e2>rhabdomyolysis</e2> possibly associated with clarithromycin and azithromycin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

414	"OBJECTIVE: To describe two cases of <e1>rhabdomyolysis</e1> in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and <e2>azithromycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

415	"OBJECTIVE: To describe two cases of <e1>rhabdomyolysis</e1> in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics <e2>clarithromycin</e2> and azithromycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

416	"OBJECTIVE: To describe two cases of <e1>rhabdomyolysis</e1> in patients taking <e2>lovastatin</e2> that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

417	"To our knowledge, these cases are the first published reports of lovastatin-induced <e1>rhabdomyolysis</e1> associated with <e2>azithromycin</e2> and clarithromycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

418	"To our knowledge, these cases are the first published reports of lovastatin-induced <e1>rhabdomyolysis</e1> associated with azithromycin and <e2>clarithromycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

419	"To our knowledge, these cases are the first published reports of <e1>lovastatin</e1> -induced <e2>rhabdomyolysis</e2> associated with azithromycin and clarithromycin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

420	"These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients <e1>died</e1> of PCP occurring during the first month of treatment with <e2>prednisone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

421	"We report the specifics of 12 cases of <e1>severe hypertension</e1> after the intraoperative use of topical phenylephrine, submucosal <e2>epinephrine</e2>, or both."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

422	"We report the specifics of 12 cases of <e1>severe hypertension</e1> after the intraoperative use of topical <e2>phenylephrine</e2>, submucosal epinephrine, or both."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

423	"<e1>Acute leukaemia</e1> during <e2>tamoxifen</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

424	"<e1>Tamoxifen</e1> is suggested to be <e2>carcinogenic</e2> both through direct genotoxic and epigenetic mechanisms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

425	"We report two cases that developed <e1>acute myeloid leukaemia</e1> (AML) during <e2>tamoxifen</e2> therapy for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

426	"We report two cases that developed acute myeloid leukaemia (<e1>AML</e1>) during <e2>tamoxifen</e2> therapy for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

427	"<e1>Relapse in the external auditory canal of acute promyelocytic leukemia</e1> after treatment with <e2>all-trans retinoic acid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

428	"This case suggests the importance of careful observation for <e1>extramedullary relapse</e1> in patients who are treated with <e2>ATRA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

429	"<e1>Cutaneous reactions</e1> to propylthiouracil and <e2>methimazole</e2> occur in 3%-5% of adults."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

430	"<e1>Cutaneous reactions</e1> to <e2>propylthiouracil</e2> and methimazole occur in 3%-5% of adults."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

431	"<e1>Generalized maculopapular and papular purpuric eruptions</e1> are perhaps the most common <e2>thionamide</e2> -induced reactions."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

432	"<e1>Propylthiouracil</e1> -induced <e2>cutaneous vasculitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

433	"The observation of <e1>cutaneous vasculitis</e1> during administration of <e2>propylthiouracil</e2> suggested that clinical awareness of this complication should be of considerable importance."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

434	"A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled <e1>heat stroke</e1> during the administration of <e2>zonisamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

435	"Children receiving <e1>zonisamide</e1> should be monitored for oligohidrosis and the development of <e2>neurological symptoms</e2> associated with an elevation of body temperature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

436	"Children receiving <e1>zonisamide</e1> should be monitored for <e2>oligohidrosis</e2> and the development of neurological symptoms associated with an elevation of body temperature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

437	"<e1>Heat stroke-like episode</e1> in a child caused by <e2>zonisamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

438	"The <e1>oligohidrosis</e1> caused by <e2>zonisamide</e2> was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

439	"<e1>Acute renal failure</e1> in a patient receiving treatment with <e2>suramin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

440	"Acute <e1>renal failure</e1> should be recognized as a potential complication of <e2>suramin</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

441	"Other potential causes of <e1>renal failure</e1> were not present in our patient and his renal function gradually recovered with the cessation of <e2>suramin</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

442	"We describe a patient with metastatic prostate cancer who developed <e1>nonoliguric renal failure</e1> during treatment with <e2>suramin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

443	"<e1>Clozapine</e1> induced <e2>polyserositis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

444	"We report the case of a patient who developed polyserositis (<e1>pericardial effusion</e1>, pleural effusion, and pericarditis) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

445	"We report the case of a patient who developed polyserositis (<e1>pericardial effusion</e1>, pleural effusion, and pericarditis) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

446	"We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and <e1>pericarditis</e1>) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

447	"We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and <e1>pericarditis</e1>) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

448	"We report the case of a patient who developed polyserositis (pericardial effusion, <e1>pleural effusion</e1>, and pericarditis) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

449	"We report the case of a patient who developed polyserositis (pericardial effusion, <e1>pleural effusion</e1>, and pericarditis) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

450	"We report the case of a patient who developed <e1>polyserositis</e1> (pericardial effusion, pleural effusion, and pericarditis) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

451	"We report the case of a patient who developed <e1>polyserositis</e1> (pericardial effusion, pleural effusion, and pericarditis) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

452	"When the disease recurred conventional <e1>amphotericin B</e1> was used again, but had to be stopped because of <e2>severe side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

453	"Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (<e1>ARA-C</e1>); among them, along with myelosuppression, five experienced <e2>fever</e2>, infectious complications, gastrointestinal tract symptoms and severe myalgias."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

454	"Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, <e1>cytosine arabinoside</e1> (ARA-C); among them, along with myelosuppression, five experienced <e2>fever</e2>, infectious complications, gastrointestinal tract symptoms and severe myalgias."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

455	"Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (<e1>ARA-C</e1>); among them, along with myelosuppression, five experienced fever, infectious complications, <e2>gastrointestinal tract symptoms</e2> and severe myalgias."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

456	"Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, <e1>cytosine arabinoside</e1> (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, <e2>gastrointestinal tract symptoms</e2> and severe myalgias."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

457	"Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (<e1>ARA-C</e1>); among them, along with myelosuppression, five experienced fever, <e2>infectious complications</e2>, gastrointestinal tract symptoms and severe myalgias."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

458	"Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, <e1>cytosine arabinoside</e1> (ARA-C); among them, along with myelosuppression, five experienced fever, <e2>infectious complications</e2>, gastrointestinal tract symptoms and severe myalgias."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

459	"Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (<e1>ARA-C</e1>); among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and <e2>severe myalgias</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

460	"Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, <e1>cytosine arabinoside</e1> (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and <e2>severe myalgias</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

461	"CONCLUSION: We believe this to be the first reported case of <e1>rhGH</e1> -induced <e2>hypercalcemia</e2> in an HIV-infected patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

462	"<e1>Hypercalcemia</e1> in an AIDS patient treated with <e2>growth hormone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

463	"The <e1>hypercalcemia</e1> responded to discontinuation of <e2>rhGH</e2> and a single dose of intravenous pamidronate disodium and has not recurred in 8 months of follow-up."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

464	"We report a male patient with advanced AIDS who developed <e1>hypercalcemia</e1> 2 weeks after institution of <e2>rhGH</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

465	"<e1>Hypersensitivity reactions</e1> to <e2>cisplatin</e2> following multiple uncomplicated courses: a report on two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

466	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested <e2>abdominal pain</e2>, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

467	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested <e2>abdominal pain</e2>, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

468	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, <e2>dyspnea</e2>, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

469	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, <e2>dyspnea</e2>, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

470	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

471	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

472	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested <e2>general erythema</e2>, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, <e2>general erythema</e2>, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

473	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested <e2>general erythema</e2>, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, <e2>general erythema</e2>, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

474	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested <e2>general erythema</e2>, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, <e2>general erythema</e2>, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

475	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested <e2>general erythema</e2>, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, <e2>general erythema</e2>, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

476	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced <e2>hypersensitivity reactions</e2> to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

477	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced <e2>hypersensitivity reactions</e2> to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

478	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and <e2>hypotension</e2>; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

479	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and <e2>hypotension</e2>; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

480	"We report an unusually short lived and asymptomatic episode of severe <e1>cisplatin</e1> -induced <e2>renal tubular salt wasting</e2> in a fit 41-year-old patient with malignant teratoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

481	"Clinicians should include <e1>phenolphthalein</e1> in their list of possible causes of drug-induced <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

482	"DISCUSSION: <e1>Phenolphthalein</e1> is the active ingredient in several over-the-counter laxative preparations and has only rarely been reported to cause <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

483	"OBJECTIVE: To report a case of <e1>phenolphthalein</e1> -induced toxic epidermal necrolysis (<e2>TEN</e2>) in a patient maintained on several other medications more commonly known to be associated with <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

484	"OBJECTIVE: To report a case of <e1>phenolphthalein</e1> -induced toxic epidermal necrolysis (<e2>TEN</e2>) in a patient maintained on several other medications more commonly known to be associated with <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

485	"OBJECTIVE: To report a case of <e1>phenolphthalein</e1> -induced <e2>toxic epidermal necrolysis</e2> (TEN) in a patient maintained on several other medications more commonly known to be associated with TEN."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

486	"<e1>Phenolphthalein</e1> -induced <e2>toxic epidermal necrolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

487	"The patient's previous <e1>rash</e1> and the temporal relation of this event and the ingestion of <e2>phenolphthalein</e2>, as well as the similarity of this case to other reports, point to <e2>phenolphthalein</e2> as the cause of TEN in this patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

488	"The patient's previous rash and the temporal relation of this event and the ingestion of <e1>phenolphthalein</e1>, as well as the similarity of this case to other reports, point to <e1>phenolphthalein</e1> as the cause of <e2>TEN</e2> in this patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

489	"<e2>Carbamazepine</e2> toxicity induced by clarithromycin coadministration in psychiatric patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

490	"<e1>Carbamazepine toxicity</e1> induced by <e2>clarithromycin</e2> coadministration in psychiatric patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

491	"During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of <e1>carbamazepine</e1>, such as drowsiness, dizziness, and <e2>ataxia</e2>, which resolved within 5 days after clarithromycin discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

492	"During <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and <e2>ataxia</e2>, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

493	"During <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and <e2>ataxia</e2>, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

494	"During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of <e1>carbamazepine</e1>, such as drowsiness, <e2>dizziness</e2>, and ataxia, which resolved within 5 days after clarithromycin discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

495	"During <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, <e2>dizziness</e2>, and ataxia, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

496	"During <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, <e2>dizziness</e2>, and ataxia, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

497	"During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of <e1>carbamazepine</e1>, such as <e2>drowsiness</e2>, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

498	"During <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as <e2>drowsiness</e2>, dizziness, and ataxia, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

499	"During <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as <e2>drowsiness</e2>, dizziness, and ataxia, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

500	"During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe <e1>toxic symptoms</e1> of <e2>carbamazepine</e2>, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

501	"During <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe <e2>toxic symptoms</e2> of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

502	"During <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe <e2>toxic symptoms</e2> of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

503	"The present report suggests that clarithromycin coadministration induces increased plasma <e1>carbamazepine</e1> concentrations, which may result in <e1>carbamazepine</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

504	"The present report suggests that clarithromycin coadministration induces increased plasma <e1>carbamazepine</e1> concentrations, which may result in <e1>carbamazepine</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

505	"The present report suggests that <e1>clarithromycin</e1> coadministration induces increased plasma carbamazepine concentrations, which may result in <e2>carbamazepine toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

506	"The present report suggests that clarithromycin coadministration induces increased plasma <e2>carbamazepine</e2> concentrations, which may result in <e2>carbamazepine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

507	"The present report suggests that clarithromycin coadministration induces increased plasma <e2>carbamazepine</e2> concentrations, which may result in <e2>carbamazepine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

508	"The present report suggests that <e1>clarithromycin</e1> coadministration induces <e2>increased plasma carbamazepine</e2> concentrations, which may result in carbamazepine toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

509	"Acute hemorrhagic gastritis associated with <e2>acetazolamide</e2> intoxication in a patient with chronic renal failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

510	"<e1>Acute hemorrhagic gastritis</e1> associated with <e2>acetazolamide</e2> intoxication in a patient with chronic renal failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

511	"As far as we know, this is the first case report of <e1>acute hemorrhagic gastritis</e1> associated with <e2>AZ</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

512	"As far as we know, this is the first case report of acute hemorrhagic gastritis associated with <e2>AZ</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

513	"She was thus diagnosed as having <e2>AZ</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

514	"We experienced a case of chronic renal failure in a patient suffering from <e1>acute hemorrhagic gastritis</e1> associated with <e2>AZ</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

515	"We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with <e2>AZ</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

516	"We thus concluded that an excessive dose of <e1>AZ</e1> had probably <e2>destroyed the gastric mucosal barrier</e2> or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

517	"We thus concluded that an excessive dose of <e1>AZ</e1> had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of <e2>hemorrhagic gastritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

518	"We thus concluded that an excessive dose of <e1>AZ</e1> had probably destroyed the gastric mucosal barrier or <e2>thrombocytopenia due to bone marrow disorder</e2> and thus eventually led to the development of hemorrhagic gastritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

519	"In association with this tocolysis, <e1>urinary calculus</e1> of <e2>magnesium ammonium phosphate</e2> occurred at 34 weeks gestation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

520	"<e1>Magnesium</e1> tocolysis as the cause of <e2>urinary calculus</e2> during pregnancy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

521	"<e1>Danazol</e1> induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

522	"On the next day, after a total dose of only 600 mg of <e1>danazol</e1>, <e2>gingival bleeding</e2> and purpura occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

523	"On the next day, after a total dose of only 600 mg of <e1>danazol</e1>, gingival bleeding and <e2>purpura</e2> occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

524	"We diagnosed this case as <e1>danazol</e1> induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

525	"It occasionally accompanies the <e1>heparin</e1> -associated <e2>thrombocytopenia</e2> and thrombosis syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

526	"It occasionally accompanies the <e1>heparin</e1> -associated thrombocytopenia and <e2>thrombosis syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

527	"<e1>Skin necrosis</e1> is a rare complication of subcutaneous <e2>heparin</e2> therapy that usually occurs at injection sites."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

528	"<e1>Skin necrosis</e1> secondary to <e2>low-molecular weight heparin</e2> in a patient with antiphospholipid antibody syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

529	"We describe a patient with the antiphospholipid syndrome who had <e1>skin necrosis</e1> develop from <e2>low-molecular weight heparin</e2> therapy at sites distant from injection sites."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

530	"Finally, <e2>reserpine</e2> toxicity, in particular central nervous system (CNS) disturbances, was reported more frequently in patients also receiving barbiturates, suggesting additive CNS effects."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

531	"A case of <e1>contact dermatitis</e1> due to <e2>sodium bisulfite</e2> in an ophthalmic solution."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

532	"Therefore, we diagnosed her eruption as <e1>contact dermatitis</e1> due to <e2>sodium bisulfite</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

533	"Therefore, we diagnosed her <e1>eruption</e1> as contact dermatitis due to <e2>sodium bisulfite</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

534	"We report a case of <e1>contact dermatitis</e1> due to <e2>sodium bisulfite</e2> in Tathion eye drops."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

535	"<e1>Acute pancreatitis</e1> after long-term <e2>5-aminosalicylic acid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

536	"<e1>Acute pancreatitis</e1> is a known, although rare, complication of <e2>mesalamine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

537	"A rechallenge, performed in both patients, confirmed the diagnosis of <e1>mesalamine</e1> -induced <e2>pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

538	"These case reports provide evidence that <e1>5-aminosalicylic acid</e1> may induce <e2>acute pancreatitis</e2> after long term treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

539	"We describe two cases of <e1>acute pancreatitis</e1> that occurred after long term <e2>mesalamine</e2> therapy for ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

540	"A 35-year-old nephrotic man developed <e1>acute renal failure</e1> with serum creatinine to 1543 micromol/l after a month of therapy with <e2>enalapril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

541	"<e1>Acute renal failure</e1> with severe tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with <e2>enalapril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

542	"Acute renal failure with <e1>severe tubulointerstitial changes</e1> in a patient with minimal change nephrotic syndrome treated with <e2>enalapril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

543	"Early <e1>ritonavir</e1> -induced <e2>maculopapular eruption</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

544	"<e1>Ritonavir</e1> should be added to the list of drugs that can induce <e2>adverse cutaneous reactions</e2> in HIV patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

545	"We report 2 cases of maculopapular eruption and <e1>fever</e1> in patients infected with human immunodeficiency virus (HIV) on the 2nd day of first administration of <e2>ritonavir</e2>, a protease inhibitor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

546	"We report 2 cases of <e1>maculopapular eruption</e1> and fever in patients infected with human immunodeficiency virus (HIV) on the 2nd day of first administration of <e2>ritonavir</e2>, a protease inhibitor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

547	"<e1>Nephropathy</e1> caused by <e2>methicillin</e2> therapy for staphylococcal septicemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

548	"Review of the literature relating to <e1>methicillin</e1> -induced <e2>nephropathy</e2> suggests a hypersensitivity origin for this disorder, but immunologic and ultrastructural investigation to date has failed to elucidate pathogenesis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

549	"A 25-year-old woman sought medical attention because of iliocaval manifestations of <e1>retroperitoneal fibrosis</e1> while she was taking <e2>methysergide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

550	"<e1>Methysergide</e1> -induced <e2>retroperitoneal fibrosis</e2>: successful outcome and two new laboratory features."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

551	"<e1>Vitiligo</e1> associated with <e2>alpha-interferon</e2> in a patient with chronic active hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

552	"We report a case of <e1>vitiligo</e1> that occurred during the second month of <e2>interferon alpha 2a</e2> therapy for chronic active hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

553	"A case is reported of an elderly woman who developed <e1>febrile agranulocytosis</e1> several weeks after commencing <e2>ticlopidine</e2> but who had a favorable outcome after cessation of that drug and treatment with filgastrim."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

554	"<e1>Agranulocytosis</e1> associated with <e2>ticlopidine</e2>: a possible benefit with filgastim."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

555	"<e1>Ticlopidine</e1> is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with severe bone marrow suppression, typically <e2>aplastic anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

556	"<e1>Ticlopidine</e1> is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with <e2>severe bone marrow suppression</e2>, typically aplastic anemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

557	"Hemodialysis was also shown to reverse <e1>ifosfamide</e1> -related <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

558	"<e1>Ifosfamide</e1> -associated <e2>neurotoxicity</e2> was noted within hours of drug administration and improved rapidly following hemodialysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

559	"PURPOSE: We evaluated the in vitro hemodialysis ratio and subsequent <e1>toxicity</e1> and pharmacokinetics of <e2>ifosfamide</e2> in an anephric patient with Wilms' tumor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

560	"The <e1>toxicity</e1> and plasma concentrations of ifosfamide, chloroacetaldehyde, and <e2>4-hydroxyifosfamide</e2> were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

561	"The <e1>toxicity</e1> and plasma concentrations of ifosfamide, <e2>chloroacetaldehyde</e2>, and 4-hydroxyifosfamide were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

562	"The <e1>toxicity</e1> and plasma concentrations of <e2>ifosfamide</e2>, chloroacetaldehyde, and 4-hydroxy<e2>ifosfamide</e2> were then determined over 24 h after a single 1.6 g/m2 dose of <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

563	"The <e1>toxicity</e1> and plasma concentrations of <e2>ifosfamide</e2>, chloroacetaldehyde, and 4-hydroxy<e2>ifosfamide</e2> were then determined over 24 h after a single 1.6 g/m2 dose of <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

564	"<e1>Toxicity</e1>, pharmacokinetics, and in vitro hemodialysis clearance of <e2>ifosfamide</e2> and metabolites in an anephric pediatric patient with Wilms' tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

565	"A 55-year-old woman developed symptoms suggestive of <e1>hepatitis</e1> 12 weeks after first receiving <e2>methyldopa</e2> for hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

566	"<e1>Methyldopa</e1> -induced <e2>liver injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

567	"Such a rapid and relentless progression of <e1>methyldopa</e1> -induced <e2>liver injury</e2> is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

568	"<e1>Acute respiratory depression</e1> as a complication of nebulised <e2>morphine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

569	"Approximately 15 min after the first administration of nebulised <e1>morphine</e1> the patient became markedly <e2>bradypneic</e2> (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

570	"Approximately 15 min after the first administration of nebulised <e1>morphine</e1> the patient became markedly bradypneic (respiratory rate: 4-5 bpm), <e2>hypotensive</e2> (BP 70/40 mmHg), and responded only partially to command."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

571	"PURPOSE: To present a case of <e1>respiratory depression</e1> following the administration of nebulised <e2>morphine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

572	"<e1>Acute dystonia</e1> with thalamic and brainstem lesions after initial <e2>penicillamine</e2> treatment in Wilson's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

573	"Acute dystonia with <e1>thalamic and brainstem lesions</e1> after initial <e2>penicillamine</e2> treatment in Wilson's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

574	"From these data, <e1>acute generalized dystonia</e1> with brainstem and thalamic lesions may occur in WD patients after an initial <e2>d-penicillamine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

575	"From these data, acute generalized dystonia with <e1>brainstem and thalamic lesions</e1> may occur in WD patients after an initial <e2>d-penicillamine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

576	"We reported 3 patients who developed <e1>acute generalized dystonia</e1> and akinetic rigid syndrome following an initial therapy with <e2>d-penicillamine</e2> 125-500 mg daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

577	"We reported 3 patients who developed acute generalized dystonia and <e1>akinetic rigid syndrome</e1> following an initial therapy with <e2>d-penicillamine</e2> 125-500 mg daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

578	"<e1>Ballistic movements</e1> due to ischemic infarcts after intravenous <e2>heroin</e2> overdose: report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

579	"Ballistic movements due to <e1>ischemic infarcts</e1> after intravenous <e2>heroin</e2> overdose: report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

580	"Patient 1 presented <e1>bilateral ballism</e1> 1 week after intravenous <e2>heroin</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

581	"<e1>Stroke</e1> is an infrequent but recognized complication of <e2>heroin</e2> addiction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

582	"Two <e1>heroin</e1> addicts, aged 34 and 19 years, developed <e2>ballistic movements</e2> after intravenous <e1>heroin</e1> overdose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

583	"A MEDLINE search identified all the reported cases of <e1>hypersensitivity reactions</e1> to <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

584	"<e1>Anaphylaxis</e1> to intravenous <e2>cyclosporine</e2> and tolerance to oral <e2>cyclosporine</e2>: case report and review."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

585	"BACKGROUND: <e1>Hypersensitivity reactions</e1> to <e2>cyclosporine</e2> are rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

586	"CONCLUSIONS: <e1>Hypersensitivity reactions</e1> to cyclosporine are due to <e2>Cremophor EL</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

587	"CONCLUSIONS: <e1>Hypersensitivity reactions</e1> to <e2>cyclosporine</e2> are due to Cremophor EL."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

588	"Fortunately, a <e1>hypersensitivity reaction</e1> to one formulation of <e2>cyclosporine</e2> does not preclude use of a different formulation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

589	"METHODS: We report a patient who had an <e1>anaphylactic reaction</e1> during the intravenous infusion of <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

590	"OBJECTIVE: To investigate the mechanisms involved in <e1>hypersensitivity reactions</e1> to <e2>cyclosporine</e2> and determine the feasibility of future <e2>cyclosporine</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

591	"OBJECTIVE: To investigate the mechanisms involved in <e1>hypersensitivity reactions</e1> to <e2>cyclosporine</e2> and determine the feasibility of future <e2>cyclosporine</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

592	"The literature search revealed 22 cases of <e1>hypersensitivity reaction</e1> to <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

593	"<e1>Prothipendylhydrochloride</e1> -induced <e2>priapism</e2>: case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

594	"We present the first case of a patient with <e1>priapism</e1> after oral intake of the phenothiazine <e2>prothipendylhydrochloride</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

595	"The chemotherapeutics, including vincristine, <e1>actinomycin D</e1>, and epirubicin in case 1 and vincristine and <e1>actinomycin D</e1> in case 2, were given before the <e2>hepatotoxicity</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

596	"The chemotherapeutics, including vincristine, <e1>actinomycin D</e1>, and epirubicin in case 1 and vincristine and <e1>actinomycin D</e1> in case 2, were given before the <e2>hepatotoxicity</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

597	"The chemotherapeutics, including vincristine, actinomycin D, and <e1>epirubicin</e1> in case 1 and vincristine and actinomycin D in case 2, were given before the <e2>hepatotoxicity</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

598	"The chemotherapeutics, including <e1>vincristine</e1>, actinomycin D, and epirubicin in case 1 and <e1>vincristine</e1> and actinomycin D in case 2, were given before the <e2>hepatotoxicity</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

599	"The chemotherapeutics, including <e1>vincristine</e1>, actinomycin D, and epirubicin in case 1 and <e1>vincristine</e1> and actinomycin D in case 2, were given before the <e2>hepatotoxicity</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

600	"We conclude that vincristine and <e1>actinomycin D</e1> were the cause of this rare from of <e2>hepatotoxicity</e2> and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

601	"We conclude that <e1>vincristine</e1> and actinomycin D were the cause of this rare from of <e2>hepatotoxicity</e2> and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

602	"Because the combination of <e1>bleomycin</e1> and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi's sarcoma, clinicians should be aware of the risk of provoking <e2>acral necrosis</e2> in patients who develop Raynaud's phenomenon under chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

603	"Because the combination of <e1>bleomycin</e1> and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi's sarcoma, clinicians should be aware of the risk of provoking acral necrosis in patients who develop <e2>Raynaud's phenomenon</e2> under chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

604	"In this report, one patient who developed <e1>gangrene</e1> after <e2>bleomycin</e2> and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

605	"In this report, one patient who developed <e1>gangrene</e1> after bleomycin and vincristine/<e2>vinblastine</e2> chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

606	"In this report, one patient who developed <e1>gangrene</e1> after bleomycin and <e2>vincristine</e2>/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

607	"In this report, one patient who developed gangrene after <e1>bleomycin</e1> and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of <e2>severe Raynaud's phenomenon</e2> related to the same regimen are presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

608	"In this report, one patient who developed gangrene after bleomycin and vincristine/<e1>vinblastine</e1> chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of <e2>severe Raynaud's phenomenon</e2> related to the same regimen are presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

609	"In this report, one patient who developed gangrene after bleomycin and <e1>vincristine</e1>/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of <e2>severe Raynaud's phenomenon</e2> related to the same regimen are presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

610	"Development of essential <e1>thrombocythemia</e1> in a patient treated with <e2>interferon alfa</e2> and pentostatin for hairy cell leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

611	"Development of essential <e1>thrombocythemia</e1> in a patient treated with interferon alfa and <e2>pentostatin</e2> for hairy cell leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

612	"Second cancers including various types of <e1>hematological malignancy</e1> have been reported in patients with hairy cell leukemia treated with chemotherapy or <e2>interferon alfa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

613	"<e1>Second cancers</e1> including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or <e2>interferon alfa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

614	"Effect of beta-blockade on symptomatic <e1>dexamethasone</e1> -induced <e2>hypertrophic obstructive cardiomyopathy</e2> in premature infants: three case reports and literature review."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

615	"One patient had a <e1>lower average heart rate</e1> and two patients had lower average mean blood pressure values during <e2>propranolol</e2> treatment, none of which was clinically significant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

616	"One patient had a lower average heart rate and two patients had <e1>lower average mean blood pressure</e1> values during <e2>propranolol</e2> treatment, none of which was clinically significant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

617	"STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and <e1>left ventricular outflow tract obstruction</e1> developed during <e2>dexamethasone</e2> treatment for bronchopulmonary dysplasia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

618	"STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant <e1>septal hypertrophy</e1> and left ventricular outflow tract obstruction developed during <e2>dexamethasone</e2> treatment for bronchopulmonary dysplasia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

619	"CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and <e1>abdominal cramping</e1> on day 6 of therapy with <e2>clindamycin</e2> vaginal cream for bacterial vaginosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

620	"CASE SUMMARY: A 25-year-old postpartum white woman developed <e1>multiple watery stools</e1> and abdominal cramping on day 6 of therapy with <e2>clindamycin</e2> vaginal cream for bacterial vaginosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

621	"<e1>Clostridium difficile toxin-induced colitis</e1> after use of <e2>clindamycin phosphate</e2> vaginal cream."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

622	"CONCLUSIONS: This report indicates <e1>clindamycin</e1> phosphate vaginal cream as the most probable cause of <e2>CDIC</e2> due to the temporal relationship between the occurrence of diarrhea and <e1>clindamycin</e1> administration, lack of concomitant medications, and documentation of C. difficile toxin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

623	"CONCLUSIONS: This report indicates <e1>clindamycin phosphate</e1> vaginal cream as the most probable cause of <e2>CDIC</e2> due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

624	"CONCLUSIONS: This report indicates <e1>clindamycin</e1> phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and <e1>clindamycin</e1> administration, lack of concomitant medications, and documentation of <e2>C. difficile toxin</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

625	"CONCLUSIONS: This report indicates <e1>clindamycin phosphate</e1> vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of <e2>C. difficile toxin</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

626	"CONCLUSIONS: This report indicates <e1>clindamycin</e1> phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of <e2>diarrhea</e2> and <e1>clindamycin</e1> administration, lack of concomitant medications, and documentation of C. difficile toxin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

627	"CONCLUSIONS: This report indicates <e1>clindamycin phosphate</e1> vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of <e2>diarrhea</e2> and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

628	"DISCUSSION: No published clinical studies in patients receiving <e1>clindamycin</e1> vaginal cream for bacterial vaginosis have documented <e2>C. difficile toxin in stool</e2> samples of patients with diarrhea."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

629	"DISCUSSION: No published clinical studies in patients receiving <e1>clindamycin</e1> vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with <e2>diarrhea</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

630	"OBJECTIVE: To report a case of <e1>toxin-positive Clostridium difficile-induced colitis</e1> (CDIC) after use of <e2>clindamycin phosphate</e2> vaginal cream."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

631	"A 54-year-old man developed <e1>TEN</e1> 4 weeks after beginning <e2>lamotrigine</e2> for complex partial seizures related to a glioblastoma multiforme brain tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

632	"Administration of <e1>lamotrigine</e1>, especially in combination with valproic acid, may lead to the development of <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

633	"Administration of lamotrigine, especially in combination with <e1>valproic acid</e1>, may lead to the development of <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

634	"<e1>Fatal toxic epidermal necrolysis</e1> related to <e2>lamotrigine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

635	"It was hypothesized that valproic acid may interfere with glucuronidation of <e1>lamotrigine</e1>, leading to increased serum <e1>lamotrigine</e1> levels, or perhaps alter the drug's metabolism, resulting in <e2>accumulation of a toxic intermediate metabolite</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

636	"It was hypothesized that <e1>valproic acid</e1> may interfere with glucuronidation of lamotrigine, leading to increased serum lamotrigine levels, or perhaps alter the drug's metabolism, resulting in <e2>accumulation of a toxic intermediate metabolite</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

637	"It was hypothesized that valproic acid may interfere with glucuronidation of <e1>lamotrigine</e1>, leading to increased serum <e1>lamotrigine</e1> levels, or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

638	"It was hypothesized that <e1>valproic acid</e1> may interfere with glucuronidation of lamotrigine, leading to <e2>increased serum lamotrigine levels</e2>, or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

639	"To date, eight cases of TEN and one of <e1>SJS</e1> related to <e2>lamotrigine</e2> administration have been reported in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

640	"To date, eight cases of <e1>TEN</e1> and one of SJS related to <e2>lamotrigine</e2> administration have been reported in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

641	"A <e1>syndrome of increased affect</e1> in response to <e2>risperidone</e2> among patients with schizophrenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

642	"Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of <e1>risperidone</e1> had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and <e2>depression</e2> and periods of crying and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

643	"Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of <e1>risperidone</e1> had an initial good response to the medication followed by development of intolerable affect, including <e2>feelings of agitation</e2> and depression and periods of crying and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

644	"Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of <e1>risperidone</e1> had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

645	"Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of <e1>risperidone</e1> had an initial good response to the medication followed by development of <e2>intolerable affect</e2>, including feelings of agitation and depression and periods of crying and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

646	"Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of <e1>risperidone</e1> had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and <e2>periods of crying</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

647	"The authors suggest that <e1>risperidone</e1> may <e2>increase affect</e2> in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

648	"<e1>Methanol</e1> toxicity can cause severe central nervous system insult in which a characteristic pattern of <e2>bilateral putaminal injury</e2> is noted on brain imaging studies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

649	"<e2>Methanol</e2> toxicity can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

650	"<e1>Methanol</e1> toxicity can cause <e2>severe central nervous system insult</e2> in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

651	"Putaminal infarct in <e2>methanol</e2> intoxication: case report and role of brain imaging studies."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

652	"<e1>Putaminal infarct</e1> in <e2>methanol</e2> intoxication: case report and role of brain imaging studies."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

653	"Theoretical basal ganglia toxicologic mechanisms of <e2>methanol</e2> poisoning are reviewed, and the role of brain imaging studies will regard to diagnosis, prognosis and impact on management is discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

654	"We present a fatal case of subacute <e1>methanol</e1> toxicity with associated diffuse brain involvement, including <e2>bilateral putaminal necrosis</e2> and cerebral edema with ventricular compression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

655	"We present a fatal case of subacute <e1>methanol</e1> toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and <e2>cerebral edema</e2> with ventricular compression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

656	"We present a fatal case of subacute <e1>methanol</e1> toxicity with associated <e2>diffuse brain involvement</e2>, including bilateral putaminal necrosis and cerebral edema with ventricular compression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

657	"We present a <e1>fatal</e1> case of subacute <e2>methanol</e2> toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

658	"We present a fatal case of subacute <e2>methanol</e2> toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

659	"We present a fatal case of subacute <e1>methanol</e1> toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with <e2>ventricular compression</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

660	"A 28 year old white schizophrenic male has been under <e1>risperidone</e1> monotherapy for about one year when he developed <e2>dyskinetic movements</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

661	"<e1>Risperidone</e1> -induced <e2>tardive dyskinesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

662	"This report presents a potential case of <e1>risperidone</e1> -induced <e2>tardive dyskinesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

663	"<e1>Increased ocular pressure</e1> in two patients with narrow angle glaucoma treated with <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

664	"A 61-year-old man developed <e1>clinical lupus syndrome</e1> with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of <e2>procainamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

665	"A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and <e1>diffuse proliferative glomerulonephritis</e1> following 26 months of <e2>procainamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

666	"A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive <e1>lupus erythematosus</e1> (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of <e2>procainamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

667	"<e1>Glomerulonephritis</e1> in <e2>procainamide</e2> induced lupus erythematosus: report of a case and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

668	"Glomerulonephritis in <e1>procainamide</e1> induced <e2>lupus erythematosus</e2>: report of a case and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

669	"We report a 76-year-old man who developed an <e1>acute blistering eruption</e1> following high-dose <e2>penicillin</e2> treatment for pneumococcal septicaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

670	"A case of prolonged <e1>suxamethonium</e1> <e2>apnoea</e2> successfully terminated by the infusion of a commercial preparation of serumcholinesterase is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

671	"<e1>Suxamethonium</e1> <e2>apnoea</e2> terminated with commercial serumcholinesterase."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

672	"<e1>Cardiac arrest</e1> associated with <e2>sulprostone</e2> use during caesarean section."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

673	"We postulate that the bolus of <e1>sulprostone</e1> resulted in possible coronary spasm that resulted in <e2>cardiac arrest</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

674	"We postulate that the bolus of <e1>sulprostone</e1> resulted in possible <e2>coronary spasm</e2> that resulted in cardiac arrest."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

675	"In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and <e1>desmethylsertraline</e1> blood levels, resulted in a <e2>doubling of the lamotrigine blood level</e2> with symptoms of toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

676	"In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the <e2>lamotrigine</e2> blood level with symptoms of toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

677	"In case 1, a total daily dose of 25 mg <e1>sertraline</e1>, with nondetectable <e1>sertraline</e1> and desmethyl<e1>sertraline</e1> blood levels, resulted in a <e2>doubling of the lamotrigine blood level</e2> with symptoms of toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

678	"In case 1, a total daily dose of 25 mg <e1>sertraline</e1>, with nondetectable <e1>sertraline</e1> and desmethyl<e1>sertraline</e1> blood levels, resulted in a <e2>doubling of the lamotrigine blood level</e2> with symptoms of toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

679	"In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and <e1>desmethylsertraline</e1> blood levels, resulted in a doubling of the lamotrigine blood level with <e2>symptoms of toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

680	"In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the <e1>lamotrigine</e1> blood level with <e2>symptoms of toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

681	"In case 1, a total daily dose of 25 mg <e1>sertraline</e1>, with nondetectable <e1>sertraline</e1> and desmethyl<e1>sertraline</e1> blood levels, resulted in a doubling of the lamotrigine blood level with <e2>symptoms of toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

682	"In case 1, a total daily dose of 25 mg <e1>sertraline</e1>, with nondetectable <e1>sertraline</e1> and desmethyl<e1>sertraline</e1> blood levels, resulted in a doubling of the lamotrigine blood level with <e2>symptoms of toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

683	"<e2>Lamotrigine</e2> toxicity secondary to sertraline."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

684	"<e1>Lamotrigine toxicity</e1> secondary to <e2>sertraline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

685	"<e1>Flutamide</e1> withdrawal syndrome is characterized by a <e2>decrease in prostate-specific antigen</e2> (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

686	"Flutamide withdrawal syndrome is characterized by a <e1>decrease in prostate-specific antigen</e1> (PSA) after <e2>flutamide</e2> withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

687	"<e2>Flutamide</e2> withdrawal syndrome is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

688	"<e1>Flutamide withdrawal syndrome</e1> is characterized by a decrease in prostate-specific antigen (PSA) after <e2>flutamide</e2> withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

689	"Prolonged prostate-specific antigen response in <e2>flutamide</e2> withdrawal syndrome despite disease progression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

690	"<e1>Prolonged prostate-specific antigen response</e1> in <e2>flutamide</e2> withdrawal syndrome despite disease progression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

691	"This case illustrates the potential <e1>decoupling of PSA response</e1> from disease status in <e2>flutamide</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

692	"We describe a patient with androgen-independent prostate cancer in whom <e1>PSA continued to decrease</e1> for a period of 15 months after <e2>flutamide</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

693	"<e1>Anaphylactic reaction</e1> to oral <e2>prednisone</e2>: a case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

694	"We describe the case of a nonatopic 17-year-old girl with bronchial asthma and aspirin intolerance who developed a dramatic <e1>anaphylactic reaction</e1> to oral <e2>prednisone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

695	"Animals treated with <e1>HAL</e1> showed a highly <e2>significant 32%-46% loss of tyrosine hydroxylase (TH) immunoreactive neurons</e2> in the substantia nigra, and 20% contraction of the TH stained dendritic arbour."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

696	"METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite <e1>vomiting</e1> within 1 to 1.5 hours after challenges with Viokase and <e2>Pancrease MT 16</e2>, but not with placebo."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

697	"METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite <e1>vomiting</e1> within 1 to 1.5 hours after challenges with <e2>Viokase</e2> and Pancrease MT 16, but not with placebo."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

698	"She was treated with <e1>Pancrease MT 16</e1>, but had consistent <e2>vomiting</e2> 1 to 2 hours after administration of enzymes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

699	"The <e1>vomiting</e1> occurred on switching to different pancreatic enzymes preparations, ie, <e2>Creon 10</e2>, Viokase, and Pancrease MT 16."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

700	"The <e1>vomiting</e1> occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and <e2>Pancrease MT 16</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

701	"The <e1>vomiting</e1> occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, <e2>Viokase</e2>, and Pancrease MT 16."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

702	"Acute <e1>valproate</e1> ingestion induces <e2>symptomatic methemoglobinemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

703	"We report for the first time the development of <e1>symptomatic methemoglobinemia</e1> after an acute ingestion of divalproex sodium (<e2>Depakote</e2>), resulting in serum concentrations 10 times greater than the therapeutic range."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

704	"We report for the first time the development of <e1>symptomatic methemoglobinemia</e1> after an acute ingestion of <e2>divalproex sodium</e2> (Depakote), resulting in serum concentrations 10 times greater than the therapeutic range."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

705	"In rare cases <e1>mitomycin C</e1> (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by <e2>hemolytic anemia</e2>, thrombocytopenia and progressive renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

706	"In rare cases mitomycin C (<e1>MMC</e1>) may induce cancer-associated hemolytic uremic syndrome, which is characterized by <e2>hemolytic anemia</e2>, thrombocytopenia and progressive renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

707	"In rare cases <e1>mitomycin C</e1> (MMC) may induce cancer-associated <e2>hemolytic uremic syndrome</e2>, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

708	"In rare cases mitomycin C (<e1>MMC</e1>) may induce cancer-associated <e2>hemolytic uremic syndrome</e2>, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

709	"In rare cases <e1>mitomycin C</e1> (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and <e2>progressive renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

710	"In rare cases mitomycin C (<e1>MMC</e1>) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and <e2>progressive renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

711	"In rare cases <e1>mitomycin C</e1> (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, <e2>thrombocytopenia</e2> and progressive renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

712	"In rare cases mitomycin C (<e1>MMC</e1>) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, <e2>thrombocytopenia</e2> and progressive renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

713	"<e1>Mitomycin C</e1> -related <e2>hemolytic uremic syndrome</e2> in cancer patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

714	"We report a case of <e1>MMC</e1> -related <e2>hemolytic uremic syndrome</e2>, and discuss the etiologic parameters, clinical aspects, prognosis and treatment modalities of this severe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

715	"<e1>CD4 T-lymphocyte depletion</e1>, myelosuppression, and subsequent severe infections are the major side effects of <e2>fludarabine phosphate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

716	"CD4 T-lymphocyte depletion, <e1>myelosuppression</e1>, and subsequent severe infections are the major side effects of <e2>fludarabine phosphate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

717	"CD4 T-lymphocyte depletion, myelosuppression, and subsequent <e1>severe infections</e1> are the major side effects of <e2>fludarabine phosphate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

718	"<e1>Severe respiratory syncytial virus pulmonary infection</e1> in a patient treated with <e2>fludarabine</e2> for chronic lymphocytic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

719	"We report here on a heretofore undescribed <e1>respiratory syncytial virus (RSV) infection</e1> in a patient with a long-standing history of refractory CLL that was treated with <e2>fludarabine phosphate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

720	"<e1>Serotonin syndrome</e1> induced by transitioning from <e2>phenelzine</e2> to venlafaxine: four patient reports."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

721	"<e1>Serotonin syndrome</e1> induced by transitioning from phenelzine to <e2>venlafaxine</e2>: four patient reports."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

722	"Although this <e1>G-CSF</e1> -driven <e2>leucocytosis</e2> was alarming it did not appear to have adversely affected the patient's prognosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

723	"<e1>Leukaemoid monocytosis</e1> in M4 AML following chemotherapy and <e2>G-CSF</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

724	"We describe a patient with M4 AML treated with standard chemotherapy followed by <e1>G-CSF</e1> who developed marked <e2>monocytosis</e2> on day 8 of <e1>G-CSF</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

725	"We describe a patient with M4 AML treated with standard chemotherapy followed by <e1>G-CSF</e1> who developed marked <e2>monocytosis</e2> on day 8 of <e1>G-CSF</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

726	"Case 2 demonstrated after 40 months on <e1>chlorambucil</e1> the presence of a <e2>balanced translocation</e2>, t (1;5) (p36;q31) in 90% of the cells."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

727	"<e1>Chromosome abnormalities</e1> after <e2>chlorambucil</e2> therapy of polycythaemia vera."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

728	"Administration of steroid and decreasing the dose of <e1>PTU</e1> produced a good clinical response and the <e2>ANCA</e2> disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

729	"<e1>Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis</e1> associated with <e2>propylthiouracil</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

730	"A teenage girl with crescentic glomerulonephritis had <e1>antineutrophil cytoplasmic antibody</e1> (ANCA) detected after she had received <e2>propylthiouracil</e2> (PTU) for hyperthyroidism without cutaneous vasculitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

731	"A teenage girl with crescentic glomerulonephritis had <e1>antineutrophil cytoplasmic antibody</e1> (ANCA) detected after she had received propylthiouracil (<e2>PTU</e2>) for hyperthyroidism without cutaneous vasculitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

732	"It was concluded that <e1>ANCA</e1> is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with <e2>PTU</e2> appeared to induce <e1>ANCA</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

733	"It was concluded that <e1>ANCA</e1> is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with <e2>PTU</e2> appeared to induce <e1>ANCA</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

734	"A <e1>drug interaction</e1> between zafirlukast and <e2>theophylline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

735	"A <e1>drug interaction</e1> between <e2>zafirlukast</e2> and theophylline."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

736	"Attempts were made to stop and then restart the <e1>theophylline</e1> therapy at progressively lower doses; however, with each attempt, the patient's <e2>reaction to the drug became more toxic</e2>, with serum <e1>theophylline</e1> levels ranging between 99.9 and 149.9 micromol/L (18 and 27 microg/mL)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

737	"Attempts were made to stop and then restart the <e1>theophylline</e1> therapy at progressively lower doses; however, with each attempt, the patient's <e2>reaction to the drug became more toxic</e2>, with serum <e1>theophylline</e1> levels ranging between 99.9 and 149.9 micromol/L (18 and 27 microg/mL)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

738	"One explanation for the noted increase in the <e2>theophylline</e2> level is that metabolism occurs mainly by cytochrome P450 (CYP 1A2), an enzyme that is known to be inhibited with high concentrations of zafirlukast."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

739	"One explanation for the noted <e1>increase in the theophylline level</e1> is that metabolism occurs mainly by cytochrome P450 (CYP 1A2), an enzyme that is known to be inhibited with high concentrations of <e2>zafirlukast</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

740	"Recently, her serum <e1>theophylline levels had increased to the toxic range</e1> (133.2 micromol/L [24 microg/mL]) shortly after the addition of zafirlukast (<e2>Accolate</e2>, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

741	"Recently, her serum <e2>theophylline</e2> levels had increased to the toxic range (133.2 micromol/L [24 microg/mL]) shortly after the addition of zafirlukast (Accolate, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

742	"Recently, her serum <e1>theophylline levels had increased to the toxic range</e1> (133.2 micromol/L [24 microg/mL]) shortly after the addition of <e2>zafirlukast</e2> (Accolate, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

743	"The noted increase in the <e2>theophylline</e2> level after zafirlukast administration is in contrast to the original reports by the manufacturer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

744	"The noted <e1>increase in the theophylline level</e1> after <e2>zafirlukast</e2> administration is in contrast to the original reports by the manufacturer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

745	"We present the first case (to our knowledge) of a potentially serious <e1>drug-drug interaction</e1> between zafirlukast and <e2>theophylline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

746	"We present the first case (to our knowledge) of a potentially serious <e1>drug-drug interaction</e1> between <e2>zafirlukast</e2> and theophylline."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

747	"A 21-year-old patient developed <e1>rhabdomyolysis</e1> during his nineteenth week of treatment with <e2>clozapine</e2> for drug-resistant schizophrenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

748	"<e1>Clozapine</e1> is speculated to cause <e2>rhabdomyolysis</e2> in patients with defective calcium-activated K+ channels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

749	"<e1>Rhabdomyolysis</e1> associated with <e2>clozapine</e2> treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

750	"We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or <e1>anticholinergic symptoms</e1> with the use of <e2>diphenhydramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

751	"We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited <e1>drug-seeking behavior</e1> or anticholinergic symptoms with the use of <e2>diphenhydramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

752	"Excluding other causes, <e1>Pentasa</e1> -associated <e2>pancytopenia</e2> was considered."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

753	"He developed fever, nausea, <e1>diarrhea</e1>, and malaise and stopped taking on the third day after commencing <e2>Pentasa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

754	"He developed <e1>fever</e1>, nausea, diarrhea, and malaise and stopped taking on the third day after commencing <e2>Pentasa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

755	"He developed fever, nausea, diarrhea, and <e1>malaise</e1> and stopped taking on the third day after commencing <e2>Pentasa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

756	"He developed fever, <e1>nausea</e1>, diarrhea, and malaise and stopped taking on the third day after commencing <e2>Pentasa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

757	"<e1>Pancytopenia</e1> associated with <e2>5-aminosalicylic acid</e2> use in a patient with Crohn's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

758	"We report a case of <e1>pancytopenia</e1> in a 23-year-old man with Crohn's disease who was treated with <e2>5-aminosalicylic acid</e2> (Pentasa; Nisshin, Tokyo, Japan) 3.0 g/day."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

759	"We report a case of <e1>pancytopenia</e1> in a 23-year-old man with Crohn's disease who was treated with 5-aminosalicylic acid (<e2>Pentasa</e2>; Nisshin, Tokyo, Japan) 3.0 g/day."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

760	"1. <e1>Changes in the plasma cortisol level</e1> were reported in a male patient with panic disorder during the period of low-dose <e2>alprazolam</e2> treatment (mean 0.62 +/- 0.15 mg/day) compared with during the period of high-dose period (mean 1.08 +/- 0.28 mg/day)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

761	"3. Thus, the <e1>decreased plasma cortisol level</e1> during <e2>alprazolam</e2> treatment of panic disorder was suggested to be caused not by symptom alleviation due to <e2>alprazolam</e2> but by <e2>alprazolam</e2> administration itself."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

762	"<e1>Decreased plasma cortisol level</e1> during <e2>alprazolam</e2> treatment of panic disorder: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

763	"We describe a renal transplant recipient maintained on <e1>cyclosporine</e1> and prednisone developing <e2>Nocardia Asteroides brain abscess</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

764	"We describe a renal transplant recipient maintained on cyclosporine and <e1>prednisone</e1> developing <e2>Nocardia Asteroides brain abscess</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

765	"Young children undergoing <e1>cisplatin</e1> chemotherapy are known to be at risk for <e2>progressive sensorineural hearing loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

766	"A 47 year-old woman who had a 4-year history of intramuscular <e1>pentazocine</e1> injections in the lower extremities, developed <e2>gradual stiffness</e2> and weakness of the lower extremities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

767	"A 47 year-old woman who had a 4-year history of intramuscular <e1>pentazocine</e1> injections in the lower extremities, developed gradual stiffness and <e2>weakness of the lower extremities</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

768	"Caution in longterm usage and early recognition of <e1>pentazocine</e1> toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced <e2>fibrous myopathy</e2> and localized neuropathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

769	"Caution in longterm usage and early recognition of <e1>pentazocine</e1> toxicity as a <e2>neuromuscular complication</e2> are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

770	"Caution in longterm usage and early recognition of <e1>pentazocine</e1> toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized <e2>neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

771	"Caution in longterm usage and early recognition of <e2>pentazocine</e2> toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

772	"<e1>Pentazocine</e1> -induced <e2>fibrous myopathy</e2> and localized neuropathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

773	"<e1>Pentazocine</e1> -induced fibrous myopathy and localized <e2>neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

774	"In two of these cases <e1>akathisia</e1> resolved after withdrawal of <e2>olanzapine</e2> and substitution by a classical or an atypical neuroleptic agent, respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

775	"Like other atypical neuroleptics <e1>olanzapine</e1> is considered to show a reduced prevalence of <e2>extrapyramidal side effects</e2> when compared to classical neuroleptic drugs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

776	"One should therefore be aware of possible <e1>extrapyramidal side effects</e1> with <e2>olanzapine</e2> that are reduced compared to classical neuroleptic drugs but not completely eliminated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

777	"<e1>Severe akathisia</e1> during <e2>olanzapine</e2> treatment of acute schizophrenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

778	"We report on three patients with acute schizophrenia, who developed <e1>severe akathisia</e1> during treatment with <e2>olanzapine</e2> (20-25 mg/d)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

779	"<e1>Seizures</e1> occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with <e2>metrifonate</e2>, an irreversible acetylcholinesterase inhibitor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

780	"However, 1 eye had <e1>vitreous hemorrhage</e1> after repeated injections of <e2>tPA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

781	"However, repeated intracameral <e1>tPA</e1> injections may cause unwanted complications such as <e2>vitreous hemorrhage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

782	"Although <e1>praziquantel</e1> administration may have been effective in killing the parasite in both patients, we are concerned about the production of marked <e2>inflammation</e2> as a result of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

783	"<e1>NMS</e1> is a drug-related response to various medications, such as <e2>Haloperidol</e2>, which the patient was receiving."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

784	"<e1>Methimazole</e1> -induced <e2>aplastic anemia</e2> in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

785	"We present a case of a 58-year-old female patient with Graves' disease who developed <e1>AA</e1> in the third exposure to <e2>methimazole</e2> (MMI)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

786	"<e1>FSGS</e1> induced by <e2>Adriamycin</e2> (Pharmacia & Upjohn, Columbus, OH) has been observed experimentally in rats."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

787	"The case demonstrates that hypersensitivity reaction to <e1>pranlukast</e1> and resultant <e2>ATIN</e2> is possible, and that periodic urine testing in patients receiving <e1>pranlukast</e1> should be considered."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

788	"The case demonstrates that hypersensitivity reaction to <e1>pranlukast</e1> and resultant <e2>ATIN</e2> is possible, and that periodic urine testing in patients receiving <e1>pranlukast</e1> should be considered."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

789	"The case demonstrates that <e1>hypersensitivity reaction</e1> to <e2>pranlukast</e2> and resultant ATIN is possible, and that periodic urine testing in patients receiving <e2>pranlukast</e2> should be considered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

790	"The case demonstrates that <e1>hypersensitivity reaction</e1> to <e2>pranlukast</e2> and resultant ATIN is possible, and that periodic urine testing in patients receiving <e2>pranlukast</e2> should be considered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

791	"<e1>Tubulointerstitial nephritis</e1> induced by the leukotriene receptor antagonist <e2>pranlukast</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

792	"Within 6 months of <e1>pranlukast</e1> withdrawal, <e2>anemia</e2> resolved and urinary sediment and renal function normalized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

793	"A 65-year-old woman with angina pectoris presented with <e1>syncope</e1> after sublingual ingestion of <e2>isosorbide dinitrate</e2> (5 mg)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

794	"Elderly patients for whom <e1>nitrate</e1> has been prescribed should be warned of the occurrence of <e2>hypotension</e2>, leading to unconsciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

795	"Elderly patients for whom <e1>nitrate</e1> has been prescribed should be warned of the occurrence of hypotension, leading to <e2>unconsciousness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

796	"In a postural challenge test after administration of <e1>isosorbide dinitrate</e1> (5 mg), <e2>blood pressure decreased</e2> from 120/67 to 65/35 mmHg, followed by syncope with a sudden decrease in pulse rate from 85 to 60 beats/min."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

797	"In a postural challenge test after administration of <e1>isosorbide dinitrate</e1> (5 mg), blood pressure decreased from 120/67 to 65/35 mmHg, followed by syncope with a <e2>sudden decrease in pulse rate</e2> from 85 to 60 beats/min."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

798	"In a postural challenge test after administration of <e1>isosorbide dinitrate</e1> (5 mg), blood pressure decreased from 120/67 to 65/35 mmHg, followed by <e2>syncope</e2> with a sudden decrease in pulse rate from 85 to 60 beats/min."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

799	"<e1>Syncope</e1> in a 65-year-old woman after <e2>nitrate</e2> ingestion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

800	"Three diabetic cases of <e1>acute dizziness</e1> due to initial administration of <e2>voglibose</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

801	"We observed 3 diabetic patients with <e1>intolerable dizziness</e1> followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, <e2>voglibose</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

802	"We observed 3 diabetic patients with intolerable dizziness followed by <e1>nausea</e1> and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, <e2>voglibose</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

803	"We observed 3 diabetic patients with intolerable dizziness followed by nausea and <e1>vomiting</e1> immediately after an initial administration of the alpha-glucosidase inhibitor, <e2>voglibose</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

804	"<e1>Naproxen</e1> -associated <e2>sudden sensorineural hearing loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

805	"<e1>Naproxen</e1> is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include <e2>tinnitus</e2> and transient hearing loss."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

806	"<e1>Naproxen</e1> is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and <e2>transient hearing loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

807	"This article reports the case of an otherwise healthy patient who experienced permanent <e1>sensorineural hearing loss</e1> after a brief course of <e2>naproxen</e2> and reviews the literature on NSAID-related permanent <e1>sensorineural hearing loss</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

808	"<e1>Dental and gingival pain</e1> as side effects of <e2>niacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

809	"The cause of these previously unreported side effects of <e1>niacin</e1> therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, <e2>hyperalgesia of sensory nerve receptors</e2>, and potentiation of inflammation in the gingiva with referral of pain to the teeth."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

810	"The cause of these previously unreported side effects of <e1>niacin</e1> therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of <e2>pain to the teeth</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

811	"The cause of these previously unreported side effects of <e1>niacin</e1> therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and <e2>potentiation of inflammation in the gingiva</e2> with referral of pain to the teeth."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

812	"The cause of these previously unreported side effects of <e1>niacin</e1> therapy is uncertain but may be related to <e2>prostaglandin-mediated vasodilatation</e2>, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of pain to the teeth."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

813	"Two 65-year-old white men with coronary heart disease, given <e1>niacin</e1> therapy for dyslipidemia for 5 months, developed <e2>intense dental and gingival pain</e2> that was associated with increases in dose and that was relieved with discontinuance of <e1>niacin</e1> treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

814	"Two 65-year-old white men with coronary heart disease, given <e1>niacin</e1> therapy for dyslipidemia for 5 months, developed <e2>intense dental and gingival pain</e2> that was associated with increases in dose and that was relieved with discontinuance of <e1>niacin</e1> treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

815	"Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and <e1>calcitriol</e1> are secondary hyperparathyroidism and vitamin D intoxication, <e2>potassium loss</e2> also should be kept in mind."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

816	"Although major hazards of treatment of hypo<e1>phosphate</e1>mic osteomalacia with <e1>phosphate</e1> and calcitriol are secondary hyperparathyroidism and vitamin D intoxication, <e2>potassium loss</e2> also should be kept in mind."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

817	"Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and <e1>calcitriol</e1> are <e2>secondary hyperparathyroidism</e2> and vitamin D intoxication, potassium loss also should be kept in mind."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

818	"Although major hazards of treatment of hypo<e1>phosphate</e1>mic osteomalacia with <e1>phosphate</e1> and calcitriol are <e2>secondary hyperparathyroidism</e2> and vitamin D intoxication, potassium loss also should be kept in mind."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

819	"Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and <e1>calcitriol</e1> are secondary hyperparathyroidism and <e2>vitamin D intoxication</e2>, potassium loss also should be kept in mind."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

820	"Although major hazards of treatment of hypo<e1>phosphate</e1>mic osteomalacia with <e1>phosphate</e1> and calcitriol are secondary hyperparathyroidism and <e2>vitamin D intoxication</e2>, potassium loss also should be kept in mind."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

821	"High-dose <e1>phosphate</e1> treatment leads to <e2>hypokalemia</e2> in hypo<e1>phosphate</e1>mic osteomalacia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

822	"It was concluded that potassium loss occurred by a non-renal (intestinal) route in <e1>phosphate</e1> -induced <e2>hypokalemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

823	"It was concluded that <e1>potassium loss</e1> occurred by a non-renal (intestinal) route in <e2>phosphate</e2> -induced hypokalemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

824	"<e1>Progressive hypokalemia</e1> developed during <e2>phosphate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

825	"The mechanism of the <e1>decrease in plasma potassium</e1> induced by <e2>phosphate</e2> treatment was investigated in a 24-year-old hypertensive patient with hypo<e2>phosphate</e2>mic osteomalacia, who was the youngest of four patients, belonging to a 23 number kindred of five generations."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

826	"<e1>Transtubular potassium gradient (TTKG) also decreased</e1> and an inverse correlation was found between TTKG and doses of <e2>phosphate</e2> (r = -0.37; p < 0.02; N = 38)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

827	"<e1>Alveolar-interstitial pneumopathy</e1> after <e2>gold</e2> -salts compounds administration, requiring mechanical ventilation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

828	"The <e1>pulmonary toxicity</e1> of <e2>gold</e2> salts is an uncommon cause of life-threatening respiratory failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

829	"The pulmonary toxicity of <e1>gold</e1> salts is an uncommon cause of life-threatening <e2>respiratory failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

830	"We report a case of severe <e1>respiratory failure</e1> due to <e2>gold</e2> salt toxicity in a patient suffering from rheumatoid arthritis requiring mechanical ventilation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

831	"As this relapse coincided with development of a strong delayed-type <e1>hypersensitivity response</e1> to <e2>tuberculin</e2> and improved after treatment with the anti-inflammatory agent oxpentifylline, it was probably caused by restoration of pathogen-specific cellular immunity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

832	"A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed postprandial hyperglycemia and <e1>glycosuria</e1> during a period of topical administration of a corticosteroid cream, <e2>halcinonide</e2> cream 0.1%, under occlusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

833	"A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed <e1>postprandial hyperglycemia</e1> and glycosuria during a period of topical administration of a corticosteroid cream, <e2>halcinonide</e2> cream 0.1%, under occlusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

834	"A second patient with a similar glucose tolerance test result showed <e1>postprandial hyperglycemia</e1> when treated similarly with <e2>betamethasone valerate</e2> cream 0.1%."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

835	"After 1 week of <e1>nefazodone</e1> therapy the patient experienced headache, <e2>confusion</e2>, and "gray areas" in her vision, without abnormal ophthalmologic findings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

836	"After 1 week of <e1>nefazodone</e1> therapy the patient experienced headache, confusion, and "<e2>gray areas</e2>" in her vision, without abnormal ophthalmologic findings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

837	"After 1 week of <e1>nefazodone</e1> therapy the patient experienced <e2>headache</e2>, confusion, and "gray areas" in her vision, without abnormal ophthalmologic findings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

838	"Coadministration of antidepressant agents such as <e1>nefazodone</e1>, or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to <e2>interfere with tacrolimus metabolism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

839	"Coadministration of antidepressant agents such as nefazodone, or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to interfere with <e2>tacrolimus</e2> metabolism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

840	"<e1>Interaction</e1> between tacrolimus and <e2>nefazodone</e2> in a stable renal transplant recipient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

841	"<e1>Interaction</e1> between <e2>tacrolimus</e2> and nefazodone in a stable renal transplant recipient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

842	"We suspect that <e1>nefazodone</e1> <e2>inhibits metabolism of tacrolimus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

843	"We suspect that nefazodone inhibits metabolism of <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

844	"We report the case of <e1>intoxication</e1> of a 41-year-old female patient suffering from major depression with <e2>mirtazapine</e2> complicated by severe hypothermia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

845	"CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute <e2>vitamin D</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

846	"CONCLUSION: We report a case of the use of pamidronate for significant <e1>hypercalcemia</e1> secondary to acute <e2>vitamin D</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

847	"Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute <e2>vitamin D</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

848	"Pamidronate therapy should be considered in patients with <e1>hypercalcemia</e1> secondary to acute <e2>vitamin D</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

849	"The patient was initially treated with hydration and <e1>furosemide</e1> but developed <e2>congestive heart failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

850	"The use of pamidronate for hypercalcemia secondary to acute <e2>vitamin D</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

851	"We report the use of pamidronate for acute, <e1>severe hypercalcemia</e1> secondary to iatrogenic <e2>vitamin D</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

852	"We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic <e2>vitamin D</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

853	"A 40-year-old man with a long standing history of rheumatoid arthritis was treated with <e1>MTX</e1> over a 6 month period and developed an <e2>overwhelming hepatic necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

854	"<e1>Methotrexate</e1> -induced <e2>hepatic necrosis</e2> requiring liver transplantation in a patient with rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

855	"<e1>MTX</e1> -induced <e2>hepatic injury</e2> and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

856	"<e1>MTX</e1> -induced hepatic injury and <e2>liver enzyme elevations</e2> have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

857	"Clinicians should be aware of the possibility that <e1>vinorelbine</e1> may cause SIADH and possibly <e2>hypokalemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

858	"Clinicians should be aware of the possibility that <e1>vinorelbine</e1> may cause <e2>SIADH</e2> and possibly hypokalemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

859	"CONCLUSIONS: Because of its structural similarity to the other vinca alkaloids, <e1>vinorelbine</e1> is believed to be responsible for <e2>SIADH</e2> in our patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

860	"OBJECTIVE: To describe onset of syndrome of inappropriate antidiuretic hormone (<e1>SIADH</e1>) associated with <e2>vinorelbine</e2> therapy for advanced breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

861	"OBJECTIVE: To describe onset of <e1>syndrome of inappropriate antidiuretic hormone</e1> (SIADH) associated with <e2>vinorelbine</e2> therapy for advanced breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

862	"<e1>Syndrome of inappropriate antidiuretic hormone</e1> associated with <e2>vinorelbine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

863	"<e1>Pirmenol hydrochloride</e1> -induced <e2>QT prolongation</e2> and T wave inversion on electrocardiogram during treatment for symptomatic atrial fibrillation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

864	"<e1>Pirmenol hydrochloride</e1> -induced QT prolongation and <e2>T wave inversion</e2> on electrocardiogram during treatment for symptomatic atrial fibrillation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

865	"Thus, an immunological mechanism might be involved in the mechanism of <e1>pirmenol</e1> -induced <e2>QT prolongation</e2> and T wave inversion on the electrocardiogram."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

866	"Thus, an immunological mechanism might be involved in the mechanism of <e1>pirmenol</e1> -induced QT prolongation and <e2>T wave inversion</e2> on the electrocardiogram."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

867	"We report on a 56-year-old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked <e1>prolongation of the QT interval</e1> and T wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral <e2>pirmenol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

868	"We report on a 56-year-old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked prolongation of the QT interval and <e1>T wave inversion</e1> on electrocardiogram was demonstrated reproducibly shortly after the administration of oral <e2>pirmenol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

869	"Disseminated muscular cysticercosis with <e1>myositis</e1> induced by <e2>praziquantel</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

870	"We describe a case of disseminated muscular cysticercosis followed by myositis (fever, <e1>diffuse myalgia</e1>, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by <e2>praziquantel</e2> therapy, an event not described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

871	"We describe a case of disseminated muscular cysticercosis followed by myositis (<e1>fever</e1>, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by <e2>praziquantel</e2> therapy, an event not described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

872	"We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and <e1>inflammatory reaction around dying cysticerci</e1>) induced by <e2>praziquantel</e2> therapy, an event not described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

873	"We describe a case of disseminated muscular cysticercosis followed by <e1>myositis</e1> (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by <e2>praziquantel</e2> therapy, an event not described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

874	"We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, <e1>weakness of the lower limbs</e1>, and inflammatory reaction around dying cysticerci) induced by <e2>praziquantel</e2> therapy, an event not described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

875	"<e1>Massive subfascial hematoma</e1> after <e2>alteplase</e2> therapy for acute myocardial infarction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

876	"Physicians should be aware of the possible association between the use of <e1>alteplase</e1> and the development of <e2>subfascial hemorrhage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

877	"The authors report a case of a patient who received <e1>alteplase</e1> for acute myocardial infarction and developed spontaneous <e2>subfascial hematoma</e2> without any evidence of direct trauma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

878	"The development of <e1>cutaneous ecchymosis</e1> associated with a sudden fall in hemoglobin after the administration of <e2>alteplase</e2> should strongly suggest the possibility of diffuse subfascial hematoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

879	"The development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of <e1>alteplase</e1> should strongly suggest the possibility of <e2>diffuse subfascial hematoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

880	"The development of cutaneous ecchymosis associated with a <e1>sudden fall in hemoglobin</e1> after the administration of <e2>alteplase</e2> should strongly suggest the possibility of diffuse subfascial hematoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

881	"A <e1>fatal case of pancytopenia</e1> due to <e2>levomepromazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

882	"A <e1>fatal pancytopenia</e1> occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, <e2>diazepam</e2> and lithium carbonate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

883	"A <e1>fatal pancytopenia</e1> occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with <e2>levomepromazine</e2>, diazepam and lithium carbonate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

884	"A <e1>fatal pancytopenia</e1> occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, diazepam and <e2>lithium carbonate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

885	"<e1>Amiodarone</e1> -induced <e2>thyrotoxicosis</e2> associated with thyrotropin receptor antibody."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

886	"<e1>Amiodarone</e1> -induced thyrotoxicosis associated with <e2>thyrotropin receptor antibody</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

887	"Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking <e1>amiodarone</e1> for 4 years, developed <e2>thyrotoxicosis</e2> with subacute onset, accompanied by transiently positive thyrotropin (TSH) receptor antibody (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

888	"Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking <e1>amiodarone</e1> for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin (TSH) receptor antibody (TRAb), or <e2>thyrotropin-binding inhibiting immunoglobulin</e2> (TBII)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

889	"Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking <e1>amiodarone</e1> for 4 years, developed thyrotoxicosis with subacute onset, accompanied by <e2>transiently positive thyrotropin (TSH) receptor antibody</e2> (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

890	"Since <e1>amiodarone</e1> was first marketed in 1992 in Japan, the incidence of <e1>amiodarone</e1> -induced thyrotoxicosis (<e2>AIT</e2>) has been increasing."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

891	"Since <e1>amiodarone</e1> was first marketed in 1992 in Japan, the incidence of <e1>amiodarone</e1> -induced <e2>thyrotoxicosis</e2> (AIT) has been increasing."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

892	"These in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with <e1>amiodarone</e1> -induced <e2>destructive thyroiditis</e2>, as reported in patients with <e2>destructive thyroiditis</e2>, such as subacute and silent thyroiditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

893	"These in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with <e1>amiodarone</e1> -induced <e2>destructive thyroiditis</e2>, as reported in patients with <e2>destructive thyroiditis</e2>, such as subacute and silent thyroiditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

894	"These in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with <e1>amiodarone</e1> -induced destructive <e2>thyroiditis</e2>, as reported in patients with destructive <e2>thyroiditis</e2>, such as subacute and silent <e2>thyroiditis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

895	"These in vitro findings and clinical course suggest that <e1>TRAb/TBII without thyroid-stimulating activity</e1> may develop in patients with <e2>amiodarone</e2> -induced destructive thyroiditis, as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

896	"CONCLUSION: <e1>Lipoid pneumonia</e1> as a result of <e2>mineral oil</e2> aspiration still occurs in the pediatric population."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

897	"In patients with swallowing dysfunction and pneumonia, a history of <e1>mineral oil</e1> use should be obtained and a diagnosis of <e2>ELP</e2> should be considered in the differential diagnoses if <e1>mineral oil</e1> use has occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

898	"In patients with swallowing dysfunction and pneumonia, a history of <e1>mineral oil</e1> use should be obtained and a diagnosis of <e2>ELP</e2> should be considered in the differential diagnoses if <e1>mineral oil</e1> use has occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

899	"In patients with swallowing dysfunction and <e1>pneumonia</e1>, a history of <e2>mineral oil</e2> use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if <e2>mineral oil</e2> use has occurred."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

900	"In patients with swallowing dysfunction and <e1>pneumonia</e1>, a history of <e2>mineral oil</e2> use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if <e2>mineral oil</e2> use has occurred."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

901	"In patients with <e1>swallowing dysfunction</e1> and pneumonia, a history of <e2>mineral oil</e2> use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if <e2>mineral oil</e2> use has occurred."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

902	"In patients with <e1>swallowing dysfunction</e1> and pneumonia, a history of <e2>mineral oil</e2> use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if <e2>mineral oil</e2> use has occurred."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

903	"<e1>Lipoid pneumonia</e1>: a silent complication of <e2>mineral oil</e2> aspiration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

904	"<e1>Mineral oil</e1>, a hydrocarbon, may not elicit a normal protective cough reflex and may <e2>impair mucociliary transport</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

905	"Our case points to the need for increased awareness by the general pediatricians of the <e1>potential hazards</e1> of <e2>mineral oil</e2> use for chronic constipation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

906	"Treatment of <e1>ELP</e1> in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of <e2>mineral oil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

907	"Treatment of ELP in children is generally supportive, with the symptoms and <e1>roentgenographic abnormalities</e1> resolving within months after stopping the use of <e2>mineral oil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

908	"We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic <e1>mineral oil</e1> ingestion presenting as asymptomatic exogenous lipoid pneumonia (<e2>ELP</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

909	"We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic <e1>mineral oil</e1> ingestion presenting as asymptomatic <e2>exogenous lipoid pneumonia</e2> (ELP)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

910	"An unusual cause of <e1>burn injury</e1>: unsupervised use of drugs that contain <e2>psoralens</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

911	"Because <e1>psoralens</e1> sensitize skin to ultraviolet A light, <e2>phototoxic reactions</e2> are the most frequent adverse effect of this treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

912	"In this article, we present the case of a vitiligo patient who was admitted to our facility with an <e1>intense burn</e1> after the topical use of <e2>8-methoxypsoralen</e2> solution as a suntanning agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

913	"Sunburn may sometimes be a major injury in <e1>psoralen</e1> users because high doses or inappropriate use of the drug may render the <e2>skin extremely sensitive</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

914	"<e1>Sunburn</e1> may sometimes be a major injury in <e2>psoralen</e2> users because high doses or inappropriate use of the drug may render the skin extremely sensitive."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

915	"CONCLUSIONS: <e1>Metoclopramide</e1> may cause reversible <e2>nonthrombocytopenic vascular-type palpable purpura</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

916	"OBJECTIVE: To report a case of reversible <e1>nonthrombocytopenic palpable purpura</e1> associated with <e2>metoclopramide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

917	"Reversible <e1>nonthrombocytopenic palpable purpura</e1> associated with <e2>metoclopramide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

918	"<e1>Lithium</e1> treatment was terminated in 1975 because of lithium intoxication with a <e2>diabetes insipidus-like syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

919	"Lithium treatment was terminated in 1975 because of <e1>lithium</e1> intoxication with a <e2>diabetes insipidus-like syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

920	"<e1>Lithium</e1> treatment was terminated in 1975 because of <e2>lithium intoxication</e2> with a diabetes insipidus-like syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

921	"Lithium treatment was terminated in 1975 because of <e2>lithium</e2> intoxication with a diabetes insipidus-like syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

922	"<e1>Eosinophilia</e1> caused by <e2>clozapine</e2> was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

923	"<e1>Eosinophilia</e1> has been encountered from 0.2 to 61.7% in <e2>clozapine</e2> -treated patients, mostly with a transient course and spontaneous remission."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

924	"Successful challenge with <e1>clozapine</e1> in a history of <e2>eosinophilia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

